<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Appl Bio Mater</journal-id><journal-id journal-id-type="iso-abbrev">ACS Appl Bio Mater</journal-id><journal-id journal-id-type="publisher-id">mt</journal-id><journal-id journal-id-type="coden">aabmcb</journal-id><journal-title-group><journal-title>ACS Applied Bio Materials</journal-title></journal-title-group><issn pub-type="epub">2576-6422</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40293247</article-id><article-id pub-id-type="pmc">PMC12093369</article-id>
<article-id pub-id-type="doi">10.1021/acsabm.5c00116</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Tailoring Alkyl Side
Chains of Ionizable Amino-Polyesters
for Enhanced In Vivo mRNA Delivery</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3934-1764</contrib-id><name><surname>L&#x000f3;pez Espinar</surname><given-names>Aida</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes2" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath2"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3617-7188</contrib-id><name><surname>Mulder</surname><given-names>Lianne M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes2" ref-type="notes">#</xref></contrib><contrib contrib-type="author" id="ath3"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9760-2272</contrib-id><name><surname>Elkhashab</surname><given-names>Mohamed</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Khan</surname><given-names>Zahra</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Czarnocki-Cieciura</surname><given-names>Mariusz</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Aburto</surname><given-names>Maria R.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath7"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0140-0121</contrib-id><name><surname>Vucen</surname><given-names>Sonja</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8607-0189</contrib-id><name><surname>Kowalski</surname><given-names>Piotr S.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><aff id="aff1"><label>&#x02020;</label>School
of Pharmacy, <institution>University College Cork</institution>, Cork T12 K8AF, <country>Ireland</country></aff><aff id="aff2"><label>&#x02021;</label>Laboratory
of Protein Structure, <institution>International Institute
of Molecular and Cell Biology</institution>, Warsaw 02-109, <country>Poland</country></aff><aff id="aff3"><label>&#x000a7;</label>APC
Microbiome Ireland, <institution>University College Cork</institution>, Cork T12 K8AF, <country>Ireland</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Anatomy and Neuroscience, <institution>University
College Cork</institution>, Cork T12 K8AF, <country>Ireland</country></aff><aff id="aff5"><label>&#x022a5;</label>SSPC,
Research Ireland Centre for Pharmaceuticals, School of Pharmacy, <institution>University College Cork</institution>, Cork T12 K8AF, <country>Ireland</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>piotr.kowalski@ucc.ie</email>.</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>04</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>19</day><month>05</month><year>2025</year></pub-date><volume>8</volume><issue>5</issue><fpage>3958</fpage><lpage>3971</lpage><history><date date-type="received"><day>20</day><month>01</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>04</month><year>2025</year></date><date date-type="rev-recd"><day>17</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0006" id="ab-tgr1"/></p><p>Lipid nanoparticles
(LNPs) containing ionizable lipids
are the
most clinically advanced platform for mRNA delivery, but their application
beyond the liver remains challenging. Polymer&#x02013;lipid hybrid
nanoparticles offer a promising alternative, combining the synthetic
versatility and unique properties of polymers with the biocompatibility
of lipid excipients. While the significance of alkyl tail design is
well-recognized for ionizable lipids, the impact of the polymer side
chain composition on interactions with lipid excipients, mRNA delivery
efficacy, and tissue specificity remains poorly understood. Here,
we focus on a class of ionizable amino-polyesters (APEs) that exhibit
features desired for potential clinical applications, including narrow
molecular weight distribution and a good safety profile, and investigate
the effect of polymer side chain composition on the formulation of
APE lipid nanoparticles (APE-LNPs) for mRNA delivery. A library of
36 APEs was synthesized via ring-opening polymerization of chemically
diverse tertiary amino-alcohols and lactone monomers with distinct
alkyl side chain compositions, including variations in length and
unsaturation. We show that optimal alkyl side chain length is critical
for the assembly of stable mRNA nanoparticles and efficient mRNA delivery
both <italic>in vitro</italic> and <italic>in vivo</italic>. Top-performing
APE-LNPs display superior delivery efficacy <italic>in vitro</italic> and in extrahepatic tissues compared to benchmark LNPs, including
DLin-MC3-DMA ionizable lipid. The polymer chain composition affects
the tissue selectivity of APE-LNPs, with shorter side chains (4&#x02013;5
carbons) effectively targeting the spleen and lungs, while longer
chains (7&#x02013;9 carbons) show enhanced liver delivery. We also
explored the relevance of lipid excipients in APE-LNPs, demonstrating
the essential role of unsaturated phospholipids in enhancing cellular
uptake and mRNA delivery, and the limited relevance of cholesterol.
These findings provide valuable insights into the design of polymers
for use in the LNP context, which could aid the development of polymeric
alternatives to ionizable lipids and expand the utility of mRNA LNP
technology to nonliver tissues.</p></abstract><kwd-group><kwd>nucleic acid delivery</kwd><kwd>mRNA</kwd><kwd>polymeric nanoparticles</kwd><kwd>polyesters</kwd><kwd>biomaterials</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>HORIZON EUROPE Health</institution><institution-id institution-id-type="doi">10.13039/100018696</institution-id></institution-wrap></funding-source><award-id>101057491</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Health Research Board, Ireland</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>EIA-2019-006</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Irish Research Council</institution><institution-id institution-id-type="doi">10.13039/501100002081</institution-id></institution-wrap></funding-source><award-id>GOIPG/2021/1649</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>HORIZON EUROPE European Research Council</institution><institution-id institution-id-type="doi">10.13039/100019180</institution-id></institution-wrap></funding-source><award-id>101041424</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mt5c00116</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mt5c00116</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The messenger RNA (mRNA) technology has
been recognized for its
global success as a vaccine against COVID-19 and its prospects to
revolutionize gene editing and cancer treatment.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> Lipid nanoparticles (LNPs) containing ionizable cationic
lipids have emerged as the most clinically advanced platform for mRNA
delivery, but their application for delivery to nonliver tissues faces
challenges related to preferential uptake by liver hepatocytes, which
can be traced even after intramuscular administration.<sup><xref ref-type="bibr" rid="ref6">6</xref>&#x02212;<xref ref-type="bibr" rid="ref9">9</xref></sup> LNP formulations, including charged lipids, enable targeting to
the lungs or spleen,<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> however, the risk of thrombosis
caused by the cationic component has been implicated as a major barrier
for safe systemic mRNA delivery to the lungs.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Recent studies also link endosomal escape, facilitated by ionizable
and cationic lipids, to inflammatory responses that can exacerbate
preexisting inflammation and should be taken into consideration for
the treatment of diseases with underlying inflammatory conditions.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Exploring alternatives to ionizable cationic
lipids is, therefore, paramount to complementing the strengths of
LNPs and helping expand the therapeutic utility of mRNA.</p><p>Polymers
have been widely utilized in drug delivery. They are chemically
versatile and possess unique physical and mechanical properties that
can be leveraged to improve mRNA delivery to extrahepatic tissues
and obtain materials with increased biocompatibility and tissue selectivity.<sup><xref ref-type="bibr" rid="ref14">14</xref>&#x02212;<xref ref-type="bibr" rid="ref17">17</xref></sup> The application of controlled polymerization methods, such as ring
opening polymerization (ROP) and radical polymerization yields more
defined polymers, significantly increasing their potential for clinical
translation and positioning them as a promising alternative to lipids
for the development of mRNA delivery systems.<sup><xref ref-type="bibr" rid="ref17">17</xref>&#x02212;<xref ref-type="bibr" rid="ref20">20</xref></sup> Polyesters are among the most
promising synthetic polymers for mRNA delivery. They degrade in a
biological milieu via hydrolysis of ester linkages and show good safety
profiles <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> To
enable mRNA encapsulation, various types of cationic polyesters have
been developed, including poly(&#x003b2;-amino esters) (PBAEs), poly(amino
coesters) (PACEs), and charge-altering releasable transporters (CARTs),
which have shown efficient mRNA delivery in different tissues.<sup><xref ref-type="bibr" rid="ref22">22</xref>&#x02212;<xref ref-type="bibr" rid="ref24">24</xref></sup> Recently, Kowalski et al. reported a new class of ionizable amino
polyesters (APEs) synthesized via ROP of lactones and tertiary amino-alcohols
that display narrow molecular weight distribution and good batch-to-batch
consistency, which are desired for clinical translation.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> The ionizable behavior of the tertiary amines
and the incorporation of lactone monomers, which are recognized as
safe by the Food and Drug Administration (FDA), contribute to their
biocompatibility.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> While polyesters used
for mRNA delivery are directly complexed with the nucleic acid, forming
a polyplex or coformulated with polyethylene glycol (PEG) or poloxamers,
APEs can be incorporated into lipid nanoparticles (APE-LNPs) with
various excipients such as cholesterol, phospholipids, and PEG-lipids,
presenting a potential alternative to ionizable lipids.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup></p><p>Previous studies have established
that the chemical composition
of APEs, in particular the presence of an alkyl side chain in the
polymer, is one of the key factors contributing to efficient mRNA
delivery to various tissues.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Similarly, the alkyl
tail composition, including unsaturation and branching, was reported
to have a significant contribution to improving the design of ionizable
lipids for mRNA delivery.<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> Despite the recognized
significance of alkyl tail composition for LNP engineering, there
is currently limited understanding of how polymer side chain composition
can influence the interaction with lipid excipients, mRNA delivery
efficacy, and tissue specificity. Closing this knowledge gap could
inform the design of polymers for use in the context of LNPs and help
extend the applicability of LNP technology to nonliver tissues.</p><p>In this study, we investigate the effect of APE side chain composition
on the design of APE-LNPs for mRNA delivery to better understand the
potential of APEs as an alternative for ionizable lipids in LNP formulation.
We synthesized a library of 36 APEs composed of six chemically diverse
tertiary amino alcohols and lactone monomers with different side chain
compositions and formulated them into APE-LNPs. We evaluated the impact
of the side chain composition on the physicochemical properties of
both the polymer and APE-LNPs, and their mRNA delivery efficacy <italic>in vitro</italic> and <italic>in vivo</italic>, supporting the significance
of the polymer side chain design. We also studied the relevance of
the helper lipids in the APE-LNP formulation, revealing their role
in enhancing the mRNA delivery efficacy.</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Design
and Characterization of the APE Library</title><p>Our
previous work demonstrated that the presence of the alkyl side chain
in the lactone monomer was critical for effective mRNA delivery by
APE-LNPs.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> Here, we aimed to better understand the
effect of the alkyl side chain composition of the APE on its physical
and thermal properties, as well as its ability to assemble into lipid
nanoparticles and deliver mRNA. To this end, a library of 36 APEs
was synthesized using six chemically diverse tertiary amino-alcohols
(AA) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A) and
lactones [&#x003b4;-hexanolactone (HL), &#x003b4;-nonalactone (NL), 5-decanolide
(DL), jasmolactone (JL), &#x003b4;-dodecalactone (DD), and &#x003b4;-tetradecalactone
(TD)] with varying alkyl side chain lengths (ranging from one to nine
carbons, C1&#x02013;C9) and compositions (including the presence of
unsaturated bonds) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). Six-membered ring lactones were selected to ensure that
polymer composition was not impacted by the dimension of the lactone
ring. Jasmolactone (JL) was included to study the effect of the unsaturated
bond in the alkyl side chain, as unsaturated alkyl tails have been
shown to enhance mRNA delivery of ionizable lipids.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> We previously observed that using amino-alcohols with a higher number
of tertiary amines improved APE mRNA delivery efficacy;<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> therefore, linear and branched amino-alcohols
(AA2, AA4, AA3, AA6, AA7) with two to four tertiary amines and hydroxyl
groups were designed and synthesized for this study. APEs were prepared
via ROP of the lactone, initiated by the tertiary AA in the presence
of triazabicyclodecene (TBD) as a catalyst (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C) as described in the <xref rid="sec4" ref-type="other">Materials
and methods section</xref>. The degree of polymerization was set to
three monomer repeat units per hydroxyl group of the initiator, which
had previously yielded APEs with the highest mRNA delivery efficacy.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Components used for the synthesis of the APEs library:
(A) amino
alcohols (AA1&#x02013;AA7) and (B) lactones [&#x003b4;-hexanolactone
(HL), &#x003b4;-nonalactone (NL), 5-decanolide (DL), jasmolactone (JL),
&#x003b4;-dodecalactone (DD) and &#x003b4;-tetradecalactone (TD)]. The
side chain composition of the lactones is highlighted in blue. (C)
Schematic of the APE synthesis via ROP. (D) Representation of the
APE-LNP composition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0001" id="gr1" position="float"/></fig><p>All APEs were characterized
before and after purification
by gel
permeation chromatography (GPC) and NMR showing narrow molecular weight
distribution (&#x00110; 1.23&#x02013;1.46), high monomer conversion (&#x0003e;80%),
and degree of polymerization (q) close to the theoretical as determined
by <sup>1</sup>H NMR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S1 and Table S1</ext-link>). The high efficacy of the ROP and good control of the polymer molecular
weight (Mn) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S2</ext-link>) featured by the
APE platform help facilitate the systematic assessment of the polymer
structure&#x02013;activity relationship (SAR) for mRNA delivery. Moreover,
all APEs displayed low batch-to-batch variability for both the polymer
properties and their corresponding LNPs (<xref rid="tbl1" ref-type="other">Tables <xref rid="tbl1" ref-type="other">1</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S2</ext-link>), which
are relevant to addressing hurdles to the translation of polymeric
nanomedicines.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Characterization
of Selected APEs
and Their APE-LNPs<xref rid="tbl1fn5" ref-type="table-fn">e</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">APE</th><th style="border:none;" align="center" char=".">Mn<xref rid="tbl1fn1" ref-type="table-fn">a</xref><xref rid="tbl1fn1" ref-type="table-fn">a</xref> [kDa]</th><th style="border:none;" align="center" char=".">&#x00110;<xref rid="tbl1fn1" ref-type="table-fn">a</xref>&#x000a0;[&#x02212;]</th><th style="border:none;" align="center" char=".">Diameter<xref rid="tbl1fn2" ref-type="table-fn">b</xref> [nm]</th><th style="border:none;" align="center" char=".">PDI<xref rid="tbl1fn2" ref-type="table-fn">b</xref><xref rid="tbl1fn2" ref-type="table-fn">b</xref> [&#x02212;]</th><th style="border:none;" align="center" char=".">&#x003b6;<xref rid="tbl1fn2" ref-type="table-fn">b</xref>&#x000a0;[mV]</th><th style="border:none;" align="center" char=".">mRNA&#x000a0;EE<xref rid="tbl1fn3" ref-type="table-fn">c</xref><xref rid="tbl1fn3" ref-type="table-fn">c</xref> [%]</th><th style="border:none;" align="center" char=".">p<italic>K</italic><sub>a</sub><xref rid="tbl1fn4" ref-type="table-fn">d</xref><xref rid="tbl1fn4" ref-type="table-fn">d</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left">AA2-HL-3</td><td style="border:none;" align="char" char=".">1.69&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="char" char=".">1.26&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="char" char=".">338&#x000a0;&#x000b1;&#x000a0;74</td><td style="border:none;" align="char" char=".">0.380&#x000a0;&#x000b1;&#x000a0;0.16</td><td style="border:none;" align="char" char=".">&#x02013;17.1&#x000a0;&#x000b1;&#x000a0;2.5</td><td style="border:none;" align="char" char=".">56.9&#x000a0;&#x000b1;&#x000a0;6.2</td><td style="border:none;" align="char" char=".">5.0&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td style="border:none;" align="left">AA2-NL-3</td><td style="border:none;" align="char" char=".">2.18&#x000a0;&#x000b1;&#x000a0;0.22</td><td style="border:none;" align="char" char=".">1.27&#x000a0;&#x000b1;&#x000a0;0.06</td><td style="border:none;" align="char" char=".">90&#x000a0;&#x000b1;&#x000a0;6</td><td style="border:none;" align="char" char=".">0.091&#x000a0;&#x000b1;&#x000a0;0.03</td><td style="border:none;" align="char" char=".">&#x02013;5.3&#x000a0;&#x000b1;&#x000a0;5.6</td><td style="border:none;" align="char" char=".">85.0&#x000a0;&#x000b1;&#x000a0;3.8</td><td style="border:none;" align="char" char=".">4.8&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td style="border:none;" align="left">AA2-DL-3</td><td style="border:none;" align="char" char=".">2.26&#x000a0;&#x000b1;&#x000a0;0.34</td><td style="border:none;" align="char" char=".">1.25&#x000a0;&#x000b1;&#x000a0;0.05</td><td style="border:none;" align="char" char=".">96&#x000a0;&#x000b1;&#x000a0;13</td><td style="border:none;" align="char" char=".">0.161&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char=".">&#x02013;4.3&#x000a0;&#x000b1;&#x000a0;2.9</td><td style="border:none;" align="char" char=".">92.3&#x000a0;&#x000b1;&#x000a0;4.5</td><td style="border:none;" align="char" char=".">4.7&#x000a0;&#x000b1;&#x000a0;0.3</td></tr><tr><td style="border:none;" align="left">AA2-JL-3</td><td style="border:none;" align="char" char=".">1.86&#x000a0;&#x000b1;&#x000a0;0.14</td><td style="border:none;" align="char" char=".">1.29&#x000a0;&#x000b1;&#x000a0;0.04</td><td style="border:none;" align="char" char=".">151&#x000a0;&#x000b1;&#x000a0;10</td><td style="border:none;" align="char" char=".">0.130&#x000a0;&#x000b1;&#x000a0;0.07</td><td style="border:none;" align="char" char=".">&#x02013;10.3&#x000a0;&#x000b1;&#x000a0;6.8</td><td style="border:none;" align="char" char=".">68.5&#x000a0;&#x000b1;&#x000a0;14.0</td><td style="border:none;" align="char" char=".">4.3&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td style="border:none;" align="left">AA2-DD-3</td><td style="border:none;" align="char" char=".">3.12&#x000a0;&#x000b1;&#x000a0;0.34</td><td style="border:none;" align="char" char=".">1.22&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="char" char=".">75&#x000a0;&#x000b1;&#x000a0;0</td><td style="border:none;" align="char" char=".">0.154&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char=".">&#x02013;4.5&#x000a0;&#x000b1;&#x000a0;3.1</td><td style="border:none;" align="char" char=".">93.3&#x000a0;&#x000b1;&#x000a0;2.3</td><td style="border:none;" align="char" char=".">4.7&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td style="border:none;" align="left">AA2-TD-3</td><td style="border:none;" align="char" char=".">4.70&#x000a0;&#x000b1;&#x000a0;0.54</td><td style="border:none;" align="char" char=".">1.21&#x000a0;&#x000b1;&#x000a0;0.00</td><td style="border:none;" align="char" char=".">77&#x000a0;&#x000b1;&#x000a0;5</td><td style="border:none;" align="char" char=".">0.173&#x000a0;&#x000b1;&#x000a0;0.04</td><td style="border:none;" align="char" char=".">&#x02013;8.7&#x000a0;&#x000b1;&#x000a0;10.2</td><td style="border:none;" align="char" char=".">94.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="char" char=".">4.3&#x000a0;&#x000b1;&#x000a0;0.4</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fn1"><label>a</label><p>Characterized by gel-permeation
chromatography.</p></fn><fn id="tbl1fn2"><label>b</label><p>Characterized
by dynamic light
scattering.</p></fn><fn id="tbl1fn3"><label>c</label><p>Characterized
by RiboGreen.</p></fn><fn id="tbl1fn4"><label>d</label><p>Characterized
by TNS assay; Mn:
number-average molecular weight, &#x00110;: dispersity, PDI: polydispersity
index, &#x003b6;: zeta potential, EE: encapsulation efficacy.</p></fn><fn id="tbl1fn5"><label>e</label><p>Data are represented as mean &#x000b1;
SD from two independently synthesized batches of each polymer and
APE&#x02013;LNPs (n = 2).</p></fn></table-wrap-foot></table-wrap><p>As thermal properties are strongly linked to the polymer&#x02019;s
chemical and physical properties, we studied the impact of alkyl side
chain composition on the glass transition temperature (Tg) of selected
APEs. Tg is defined as the temperature at which a polymer transitions
from a glassy state to a rubbery state. This transition is influenced
by structural factors that prevent alignment among the macromolecules
and promote the mobility of the polymer chains, e.g., pendant side
groups generally lead to a lower Tg.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Hence,
it is expected that longer side chains with higher rotational freedom
would decrease the Tg of the APE, while the presence of unsaturated
bonds or bulky groups would introduce rigidity to the side chain,
resulting in an increased Tg of the polymer.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> All studied APEs were amorphous (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S3</ext-link>) with Tg ranging from &#x02212;45&#x000b0;C to &#x02212;65&#x000b0;C (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). We found that
the Tg of the polymers was primarily affected by the composition of
the side chain rather than the amino alcohol. Increasing the length
of the alkyl side chain corresponded to significantly lower Tg (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). The incorporation
of an unsaturated bond in the polymer side chain (AA1-JL-3, AA3-JL-3,
and AA4-JL-3) significantly increased the Tg compared with APEs with
corresponding saturated side chains (AA1-DL-3, AA3-DL-3, and AA4-DL-3),
likely due to the higher rigidity of the double bond. We also confirmed
that the MW of APE did not impact Tg by comparing polymers synthesized
with three (AA1-DD-3 and AA3-DD-3) and ten monomer repeat units (AA1-DD-10
and AA3-DD-10, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Table S3</ext-link>). Our data show that the
thermal properties of APEs are strongly linked to their side chain
composition, and Tg analysis via differential scanning calorimetry
can be used as a reliable method to complement the evaluation of APE
composition and batch-to-batch consistency, enabling robust characterization
of these polymers.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Glass transition temperature (Tg) analysis. (A) Tg of
polymers
composed of amino-alcohols AA1, AA3, and AA4 and 3 repeat units of
the lactone with different lengths of the alkyl side chain (from shortest
to longest; HL &#x0003c; NL &#x0003c; JL = DL &#x0003c; DD); * <italic>p</italic> &#x0003c; 0.0001. (B) Tg for AA1-DD and AA4-DD with the degree of polymerization
corresponding to 3 and 10 monomer repeat units, not significant (ns); <italic>p</italic> &#x0003e; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0002" id="gr2" position="float"/></fig></sec><sec id="sec2.2"><title>The APE Side Chain Composition
Impacts the Physicochemical Properties
of APE-LNPs</title><p>Polymer&#x02013;lipid hybrid nanoparticles present
a promising strategy for mRNA delivery, allowing the integration of
the synthetic versatility and unique properties of polymers with the
modularity and biocompatibility of lipid excipients.<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> Our previous work and others demonstrated that APEs synthesized
with &#x003b5;-caprolactone (CL, no side chain) had an impaired ability
to form stable lipid nanoparticles with mRNA, regardless of the polymer
MW, and required the presence of a side chain, suggesting that the
composition of the alkyl side chain could play an important role in
APEs&#x02019; interaction with lipid excipients.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> To better understand the impact of APE side chain composition on
facilitating assembly into LNPs, we systematically investigated the
physicochemical properties and mRNA delivery capacity of 36 APE-LNPs.
The library of APEs was formulated into nanoparticles containing mRNA
encoding firefly luciferase (FLuc), along with 1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine (DOPE), cholesterol, and
1,2-dimyristoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine-<italic>N</italic>-[methoxy-(polyethylene glycol)-2000] (ammonium salt) (C14-PEG<sub>2000</sub>) using microfluidic mixing. Nanoparticles were prepared
at a 9:1 ratio of tertiary amines in the amino polyester to mRNA phosphate
groups (N/P; <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D).</p><p>We found that the APE alkyl side chain length had a significant
impact on the APE-LNPs&#x02019; physicochemical properties, including
their hydrodynamic diameter, surface charge, and mRNA encapsulation
efficacy. In particular, APE-LNPs formulated with HL polymers containing
single-carbon (C1) side chains were significantly larger and more
polydisperse (hydrodynamic diameters ranging from 150 to 400 nm and
PDIs from 0.2 to 0.6) compared to APE-LNPs formulated with polymers
containing side chains between four and nine carbons (C4&#x02013;C9).
The latter yielded homogeneous nanoparticles ranging from 65 to 140
nm in diameter and PDIs below 0.2 (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>Aand <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4A</ext-link>). Cryogenic
electron microscopy (cryo-TEM) also confirmed the different morphology
of the APE-LNPs composed of HL polymer, indicative of impaired nanoparticle
assembly and poor mRNA encapsulation (presence of multi- and unilamellar
vesicles with low electron density; <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>G and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S5</ext-link>). Overall,
a strong negative correlation between alkyl side chain length and
the size of APE-LNPs was observed for all polymers, demonstrating
the critical importance of the APE side chain design for their ability
to form nanoparticles with lipid excipients (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>B and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4B</ext-link>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Characterization
of physicochemical properties and <italic>in vitro</italic> mRNA delivery
capabilities of APE-LNPs. (A) Hydrodynamic diameter
(nm) and polydispersity index (PDI) of APE-LNPs formulated with polymers
AA1, AA2, and AA4 with varying lengths of the alkyl side chain. Data
are presented as mean &#x000b1; SD; <italic>n</italic> = 3; ****<italic>p</italic> &#x0003c; 0.000 1. (C) Surface charge of APE-LNPs. Data are
presented as mean &#x000b1; SD; <italic>n</italic> = 2. (E) mRNA encapsulation
efficacy of APE-LNPs measured by Ribogreen assay. Data are presented
as mean &#x000b1; SD; <italic>n</italic> = 3; ns, <italic>p</italic> &#x0003e;
0.05, *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.001,
****<italic>p</italic> &#x0003c; 0.0001. Spearman correlation coefficient
between polymer alkyl side chain length and (B) hydrodynamic diameter,
(D) surface charge, and (F) mRNA encapsulation of APE-LNPs. (G) Representative
Cryo-TEM images of AA2-HL-3 and AA2-NL-3 nanoparticles. The scale
bar represents 20 nm. (H) <italic>In vitro</italic> evaluation of
mRNA delivery efficacy by APE-LNPs containing FLuc mRNA in HeLa cells.
Cells were transfected for 24 h with 50 ng of FLuc mRNA. Data are
presented as mean relative luminescence (normalized to viability); <italic>n</italic> = 3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0003" id="gr3" position="float"/></fig><p>Moreover, the APE-LNPs
composed of HL polymers
(AA1-HL-3 and AA4-HL-3)
showed limited stability over time compared to DL-based polymers (AA1-DL-3
and AA4-DL-3), increasing in size and polydispersity when stored in
PBS (pH 7.4) at 4 &#x000b0;C for up to 28 days (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S6</ext-link>). This data confirm that the APE alkyl side chain length
also plays a role in LNP stability, and polymers with short (e.g.,
C1) or no side chains display limited size stability or tend to form
aggregates.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup></p><p>The surface charge (&#x003b6;)
of APE-LNPs ranged from &#x02212;20
to 10 mV (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>C and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4C</ext-link> ), and a positive correlation
was observed between the polymer alkyl side chain length and the &#x003b6;-potential
(<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>D and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4D</ext-link>). The mRNA encapsulation efficiency (EE)
of the APE-LNPs was between 20 and 95% and also positively correlated
with the alkyl side chain length. We hypothesize that APE-LNPs with
low EE (&#x0003c;60%) may exhibit a decreased surface charge due to potential
interference of the nonencapsulated mRNA. Polymers with side chains
containing four or more carbons yielded particles with significantly
increased EE (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>E,F and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4E,F</ext-link>). We also observed that
the presence of an unsaturated bond in the APE alkyl side chain (JL)
significantly decreased the mRNA EE and &#x003b6;-potential for the
majority of the APE-LNPs compared to its saturated counterpart (DL)
but had a modest impact on the particle size in contrast to HL polymers
(<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>A,C,E and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S4A,C,E</ext-link>,). Liu etal. reported that cis double
bonds introduced into polyesters functionalized with fatty acid chains
impeded the packing of side chains and polymer, such behavior could
potentially contribute to the lower mRNA EE of JL APE-LNPs but trans
double bonds may not display the same behavior.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></p></sec><sec id="sec2.3"><title>Polymer Alkyl Side Chain Length Impacts the
mRNA Delivery Efficacy
of APE-LNPs In Vitro</title><p>To establish the impact of the APE side
chain composition on mRNA delivery efficacy, the library of APE-LNPs
was formulated with Firefly Luciferase (Fluc) mRNA and evaluated in
three relevant cell types, including HeLa cells, human leukemia monocytic
cells (THP-1), and human umbilical vein endothelial cells (HUVECs).
We found that the length of the polymer alkyl side chain played a
major role in the efficacy of mRNA delivery by the APE-LNPs. APEs
with C4 and C5 side chains (NL and DL) exhibited the highest efficacy,
whereas polymers with a C1 side chain (HL) were unable to deliver
the mRNA (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>H and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S7A,B</ext-link>), likely due to impaired interaction
of the polymer with lipid excipients, resulting in low EE and large
particles with limited stability (<xref rid="tbl1" ref-type="other">Tables <xref rid="tbl1" ref-type="other">1</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S2</ext-link>). Similarly,
the presence of an unsaturated bond in the polymer side chain (JL)
impaired the mRNA delivery efficacy of most APE-LNPs compared to its
saturated counterpart (DL) (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>H and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S7A,B</ext-link>). The lower
performance of the JL polymers could be linked to impaired mRNA encapsulation;
however, Fenton et al., showed that the placement, cis/trans geometry,
and the optimal number of alkenes per tail were also critical for
efficient mRNA delivery with ionizable lipids.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Generally, APE-LNPs containing polymers with 3 or 4 tertiary
amines showed better mRNA delivery efficacy compared to APE-LNPs containing
2 tertiary amines corroborating our previous results.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Top-performing APE-LNPs containing AA2 and AA3 polymers
with C4 and C5 side chains (NL, DL) showed up to 10-fold higher transfection
efficacy in HeLa cells than polymers containing longer tails C7 and
C9 (DD and TD) selected from the previous study (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>H).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Compared to benchmark LNPs, including C12&#x02013;200 and MC3 ionizable
cationic lipids, the AA2-LNPs showed up to 6- and 400-fold more efficient
mRNA delivery in HeLa cells, respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S7C</ext-link>). The majority of APE-LNPs were well tolerated in all the
cell lines, with notable toxicity for polymers containing 4 tertiary
amines (AA3) compared to control LNPs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S8A&#x02013;C</ext-link>). Interestingly, the mRNA delivery efficacy of
some APE-LNPs was found to be cell-type dependent, with AA7-NL-3 and
AA7-DL-3 only showing efficacy in HeLa cells (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>H and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S7A,B</ext-link>).
These data show that the optimal side chain design is required for
each polymer to maximize the potency of mRNA delivery to different
cells by APE-LNPs.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Branching of ionizable
lipids tails was found to impact the volumetric ratio occupied by
the headgroup and alky tails influencing the transition to inverted
hexagonal phase H<sub>II</sub> and facilitating ionization at pH 5,
leading to enhanced endosomal escape.<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> The best-performing
APE-LNPs showed higher ionization scores at pH 5 than the HL and JL
APE-LNPs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S9C,D</ext-link>); hence, we hypothesize
that side chain design may help facilitate better endosomal escape
and consequently enhanced mRNA delivery. The APE side chain could
also potentially contribute to improved endosomal escape through balancing
the hydrophobicity of the polymer or changing its degradation profile
by controlling access of water to an ester bond.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup></p></sec><sec id="sec2.4"><title>Efficient mRNA Delivery of APE-LNPs Requires
the Incorporation
of Unsaturated Phospholipids</title><p>Helper lipids, including a phospholipid,
cholesterol, and PEGylated lipid, have been widely used in ionizable
lipid mRNA formulations to improve nanoparticle stability and biodistribution
and aid in endosomal escape. However, their integration within polymeric
delivery systems is less common. Cationic polyesters are predominantly
complexed with the mRNA, forming a polyplex or coformulated with PEG-lipids
or poloxamers.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> Given the ability of APEs to form stable lipid&#x02013;polymer hybrid
nanoparticles, we set out to establish the role of helper lipids (phospholipid
and cholesterol) in facilitating mRNA delivery by APE-LNPs. One of
the top-performing polymers, AA2-NL-3, was formulated into APE-LNPs
with Cy5-labeled FLuc mRNA and C14-PEG2000 in the presence or absence
of DOPE and/or cholesterol (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Table S4</ext-link>).
In the absence of both helper lipids, we observed a 97% reduction
in cellular uptake of APE-LNPs and a 120-fold reduction in FLuc mRNA
expression in HeLa cells (<xref rid="fig4" ref-type="fig">Figures <xref rid="fig4" ref-type="fig">4</xref></xref>A&#x02013;D and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S11</ext-link>). Lipid
nanoparticles formulated with a structurally different polymer (AA4-NL-3)
displayed nearly identical behavior, confirming the critical role
of these excipients for APE-mediated mRNA delivery (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S12A</ext-link>). Zooming in on the role of individual components,
the removal of cholesterol did not significantly alter cellular uptake
of AA2-NL-3-LNPs and only resulted in a 2-fold reduction in FLuc expression,
suggesting that cholesterol could aid in facilitating the endosomal
escape but may not be necessary for APE-LNP-mediated mRNA delivery.
We found that transfection efficacy was mostly dependent on the phospholipid
(DOPE), since its removal impaired the cellular uptake of the AA2-LNPs
by 70% and reduced FLuc expression by 60-fold as compared to APE-LNPs
containing all helper lipids. Formulations lacking DOPE displayed
similar size and EE compared to four-component APE-LNPs, but their
&#x003b6;-potential decreased from approximately &#x02212;5 to &#x02212;15
mV, which could contribute to the reduced cellular uptake across negatively
charged cell membranes (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S10</ext-link>). Noting
the importance of the phospholipid, we further investigated the impact
of phospholipid composition on APE-LNP-mediated mRNA delivery. Phospholipid
head groups and saturation of the alkyl tails were shown to have a
strong impact on the bilayer-forming properties and endosomal escape
of the LNP.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> We, therefore, compared APE-LNPs
containing 1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphocholine
(DOPC), 1,2-distearoyl-<italic>sn</italic>-glycero-3-phosphocholine
(DSPC), or DOPE (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>E,F). DOPE and DSPC have been predominantly used to formulate LNPs
with ionizable lipids.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> DSPC enhances
bilayer membrane stability relating to its high phase transition temperature,
whereas DOPE has a low phase transition temperature and was reported
to introduce membrane curvature and increase tension, thereby promoting
inverted hexagonal phase transition.<sup><xref ref-type="bibr" rid="ref48">48</xref>&#x02212;<xref ref-type="bibr" rid="ref50">50</xref></sup> In comparison to DOPE,
the incorporation of DSPC drastically reduced the mRNA delivery efficacy
of APE-LNPs by 94% (16-fold), followed by a 30% decrease upon substitution
with DOPC. These data suggest that APEs prefer interaction with unsaturated
phospholipids displaying low transition temperatures (Tm (&#x000b0;C):
DOPE &#x02212;16, DOPC &#x02212;17, and DSPC +55)<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> that can promote the formation of fluid bilayers. These
features aid in driving inverted hexagonal phase transition and, in
turn, facilitate improved endosomal membrane fusion, allowing for
more efficient mRNA delivery of APE-LNPs incorporating DOPE or DOPC
as compared to DSPC.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Investigation of the role of helper lipids in the APE-LNPs
formulation.
Hela cells transfected with AA2-NL-3 APE-LNPs with or without DOPE
and/or cholesterol containing Cy5-labeled FLuc mRNA. (A) Normalized
luminescence signal measured 24 h after transfection with 50 ng of
FLuc mRNA. Data are presented as mean relative luminescence &#x000b1;
SD; <italic>n</italic> = 3. (B) Flow cytometry analysis of the uptake
of 250 ng APE-LNPs containing Cy5 mRNA, 24 h after transfection. Mean
fluorescence intensities of Cy5 are presented relative to 4-component
APE-LNP (4C) as mean &#x000b1; SD; <italic>n</italic> = 3. (C) Representative
histograms of Cy5+ cell population. (D) Representative images of the
uptake of APE-LNPs into HeLa cells with DAPI (blue) and Cy5 mRNA (magenta).
Scale bars represent 20 &#x003bc;m. ****<italic>p</italic> &#x0003c; 0.0001.
(E) Chemical structure of phospholipids DOPE, DOPC, and DSPC. (F)
mRNA delivery efficacy of APE-LNPs incorporating these different phospholipids.
Normalized luminescence signal measured 24 h after transfection of
HeLa cells with APE-LNPs containing 50 ng of FLuc mRNA. Data are presented
as mean relative luminescence &#x000b1; SD; <italic>n</italic> = 3.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0004" id="gr4" position="float"/></fig></sec><sec id="sec2.5"><title>Polymer Side Chain Length Influences In Vivo
mRNA Delivery Efficacy
of APE-LNPs in Different Tissues</title><p>AA2 polymers were selected
for <italic>in vivo</italic> studies to explore the effect of polymer
side chain length on the mRNA delivery and distribution of the APE-LNPs.
C57BL/6 mice were injected intravenously via the tail vein with APE-LNPs
containing FLuc mRNA at a 0.5 mg kg<sup>&#x02013;1</sup> dose. We observed
that the polymer side chain length influenced the tissue selectivity
and efficacy of mRNA delivery (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A). AA2-HL-3 LNPs were ineffective, corroborating our <italic>in vitro</italic> findings showing that a side chain longer than
one carbon is needed to allow mRNA delivery.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> APE-LNPs with side chain lengths ranging from C4 to C9 could efficiently
deliver mRNA to the lungs and spleen and target the liver, with differences
in organ selectivity depending on the side chain length (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B,C). AA2-NL-3 and
AA2-DL-3, with C4 and C5 side chains, respectively, predominantly
delivered mRNA to the spleen and lungs. In contrast, AA2-DD-3 and
AA2-TD-3, with C7 and C9 side chains, showed enhanced delivery to
the liver, accompanied by a decrease in delivery to other organs (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). Overall, mRNA
delivery to the liver of AA2-DD-3 was significantly less efficient
(2.4-fold) compared to liver-targeting MC3 LNPs and could be further
reduced by 3.5-fold by fine-tuning the side chain composition, as
demonstrated with AA2-DL-3 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). This emphasizes the potential to develop APEs as
an mRNA delivery platform to nonliver tissues. Liver targeting could
potentially be further reduced by excluding cholesterol from APE-LNP
formulations due to their low reliance on this excipient for mRNA
delivery, as shown <italic>in vitro</italic> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B). This strategy was recently employed by
Su et al., to decrease liver accumulation for LNPs containing permanently
charged lipids.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Based on our findings,
we also investigated if the 4C side chain can improve mRNA delivery
of the previously reported lung-targeting AA3-DD-3 LNP with a 7C side
chain and found that reducing side chain length resulted in a 2.4-fold
increase in mRNA delivery to the lungs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S13</ext-link>). This reinforces the importance of optimizing the side
chain composition to improve the <italic>in vivo</italic> performance
of APE-LNPs.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Optimizing the hydrophobicity
of polyesters by Yu et al. led to enhanced performance of mRNA polyplexes
in the lungs, suggesting the contribution of polymer hydrophobic domains
in interactions with serum or cell components, although the mechanism
remains unclear.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Notably, the effect
of changes in hydrophobicity on the ability of LNPs to target specific
organs may differ between biomaterials. Liu et al. reported that multitailed
ionizable phospholipids (iPhos) with short alkyl tails predominantly
targeted the liver, while long tails preferentially targeted the spleen.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup></p><fig id="fig5" position="float"><label>Figure 5</label><caption><p><italic>In vivo</italic> evaluation of APEs. C57BL/6 mice
were
injected via tail vein with 0.5 mg/kg of APE-LNPs containing mRNA
encoding Firefly luciferase (FLuc) mRNA and imaged by IVIS after 6h.
(A) Representative images of FLuc mRNA expression within the tissues;
Lu: lungs, H: heart, Li: liver, S: spleen, K: kidney, P: pancreas.
(B) Quantification of FLuc mRNA expression in selected tissues. Data
are presented as mean &#x000b1; SD; <italic>n</italic> = 3. Ns, <italic>p</italic> &#x0003e; 0.05, *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.001, ****<italic>p</italic> &#x0003c; 0.0001. (C) Quantification
of FLuc mRNA expression in selected organs shown as % of Total flux.
Data are presented as mean &#x000b1; SD; <italic>n</italic> = 3. (D)
Quantification of DiR fluorescence expression in selected organs shown
as % of Total flux. Data are presented as mean &#x000b1; SD; <italic>n</italic> = 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_0005" id="gr5" position="float"/></fig><p>To gain further insights
into the differences in
mRNA delivery
to different organs, we studied the biodistribution of APE-LNPs labeled
with the fluorescent dye DiR. We compared polymers with a 4C side
chain (AA2-DL-3), which exerted selectivity to the lungs and spleen,
and the long (C9) side chain (AA2-TD-3), which showed more mRNA delivery
to the liver (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). The measurement of DiR fluorescence showed that, in both cases,
the majority of APE-LNPs accumulated in the liver (&#x000b1;75%) with
lower distribution to the spleen (10&#x02013;15%) and lungs (5&#x02013;10%)
(<xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig">5</xref></xref>D and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S14A,B</ext-link>). Our biodistribution data indicate that
there is no direct correlation between APE-LNP uptake by certain tissues
and functional mRNA delivery. However, these results corroborate other
findings with lipid and polymeric nanoparticles, where organs with
the highest accumulation did not exhibit the highest mRNA expression.<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref53">53</xref></sup> We speculate that organ selectivity
may relate to alterations in the formation of the protein corona resulting
from the alkyl side chain&#x02019;s impact on the chemical composition
and physicochemical properties of APE-LNPs, but detailed mechanistic
studies are required to confirm this hypothesis.<sup><xref ref-type="bibr" rid="ref55">55</xref>,<xref ref-type="bibr" rid="ref56">56</xref></sup> Further studies are needed to determine the likely complex mechanism
behind this <italic>in vivo</italic> behavior of both lipid and polymer
delivery systems.</p><p>The apparent acid dissociation constant (p<italic>K</italic><sub>a</sub>) of LNPs containing ionizable lipids was shown
to affect
mRNA delivery to different organs.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> We
therefore studied the impact of the APE alkyl side chain composition
on the p<italic>K</italic><sub>a</sub> of APE-LNPs using 2-(<italic>p</italic>-toluidino)naphthalene-6-sulfonic acid (TNS) assay.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> The apparent p<italic>K</italic><sub>a</sub> of APE-LNPs ranged from 3 to 6 and was not significantly affected
by the length of the polymer side chain (<xref rid="tbl1" ref-type="other">Tables <xref rid="tbl1" ref-type="other">1</xref></xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">S2, and Figure S9A,B</ext-link>), but rather mainly driven by the composition of the tertiary amino-alcohol.
AA2-LNPs evaluated <italic>in vivo</italic> exhibited comparable p<italic>K</italic><sub>a</sub> between 4 and 5 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Figure S15D</ext-link>), which could potentially explain their inefficient mRNA
delivery to the liver despite accumulation in liver tissue, as the
optimal p<italic>K</italic><sub>a</sub> reported for liver-targeting
LNPs is between 6.2 and 6.5.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> However,
the link between p<italic>K</italic><sub>a</sub> and mRNA delivery
to nonliver tissues has not been well established. As shown by Dilliard
et al., LNP formulations including charged lipids with p<italic>K</italic><sub>a</sub> between 2 and 6 tend to target the spleen, while with
p<italic>K</italic><sub>a</sub> above 7 tend to deliver to the lungs,
which does not correspond with our findings.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> As indicated above, the polymer and lipid nanoparticle composition
may also be relevant for interaction with key serum components influencing
the formation of the protein corona on the nanoparticle surface, which
needs to be further investigated.<sup><xref ref-type="bibr" rid="ref58">58</xref>&#x02212;<xref ref-type="bibr" rid="ref60">60</xref></sup></p></sec></sec><sec id="sec3"><title>Conclusion</title><p>In this study, we show the impact of APE
alkyl side chain composition
on the design of APE-LNPs for mRNA delivery to nonliver tissues and
demonstrate the potential of low molecular weight APEs to be developed
as an alternative to ionizable lipids in LNP formulation. Our findings
reveal that the optimal alkyl side chain length is critical for the
assembly of stable mRNA nanoparticles and their ability to efficiently
deliver mRNA both <italic>in vitro</italic> and <italic>in vivo</italic>. Tissue selectivity of mRNA APE-LNPs is also impacted by the polymer
alkyl side-chain length, where polymers with short carbon side chains
(4&#x02013;5 carbons) target the spleen and lungs more effectively
than polymers with longer side chains (7&#x02013;9 carbons), which
show increased mRNA delivery to the liver. We also unraveled the relevance
of helper lipids in APE-LNP formulation, in particular the critical
role of the unsaturated phospholipids in cellular uptake and mRNA
delivery efficacy, as well as the low dependency of APE-LNPs on cholesterol,
which may be further leveraged to reduce liver uptake. Altogether,
our findings provide valuable insights into the design of polymers
for use in the context of LNPs, which can help identify alternatives
to ionizable lipids and expand the therapeutic utility of mRNA LNPs
beyond the liver.</p></sec><sec id="sec4"><title>Materials and Methods</title><sec id="sec4.1"><title>Materials</title><p>&#x003b4;-Hexanolactone
(HL) was purchased
from Fisher Scientific Ireland. &#x003b4;-Nonalactone (NL), 5-decanolide
(DL), jasmolactone (JL), &#x003b4;-dodecalactone (DD), &#x003b4;-tetradecalactone
(TD), <italic>N</italic>,<italic>N</italic>,<italic>N</italic>&#x02032;,<italic>N</italic>&#x02032;-tetrakis(2-hydroxyethyl)ethylenediamine amines
used for the synthesis of the amino-alcohols 3,3&#x02032;-diamino-<italic>N</italic>-methyldipropylamine, tris[2-(methylamino)ethyl]amine, <italic>N,N</italic>-dimethylethylenediamine, <italic>N,N&#x02019;</italic>-dimethylethylenediamine, 1,4,7-triazacyclononaneand, and the catalyst
1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) were purchased from Sigma-Aldrich
Ireland. Custom amino-alcohols, 3,3&#x02032;,3&#x02032;&#x02019;,3&#x02032;&#x02019;&#x02019;-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrakis(propan-1-ol),
3,3&#x02032;,3&#x02032;&#x02019;-((nitrilotris(ethane-2,1-diyl))tris(methylazanediyl))tris(propan-1-ol),
3,3&#x02032;-((2-(dimethylamino)ethyl)azanediyl)bis(propan-1-ol), 3,3&#x02032;-(ethane-1,2-diylbis(methylazanediyl))bis(propan-1-ol),
and 3,3&#x02032;,3&#x02032;&#x02019;-(1,4,7-triazonane-1,4,7-triyl)tris(propan-1-ol)
were synthesized according to the procedure described below. All the
solvents were purchased from Sigma-Aldrich Ireland at ACS grade. All
chemical reagents were used as received with no further purification.
The benchmark ionizable lipids 1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol
(C12&#x02013;200), and [(2R)-2,3-di(tetradecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl
phosphate (MC3) were purchased from BroadPharma (San Diego, CA) and
CordenPharma (Basel, Switzerland), respectively. The lipids 1,2-dioleoyl-<italic>sn</italic>-glycero-3-phosphoethanolamine (DOPE), 1,2-di(9Z-octadecenoyl)-<italic>sn</italic>-glycero-3-phosphocholine (DOPC), 1,2-dioctadecanoyl-<italic>sn</italic>-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene
glycol-2000 (DMG-PEG<sub>2000</sub>) 1,2-dimyristoyl-<italic>sn</italic>-glycero-3- phosphoethanolamine-<italic>N</italic>-[methoxy-(polyethylene
glycol)-2000] (ammonium salt) (C14-PEG<sub>2000</sub>) and the sterol
cholesterol were purchased from Avanti. The TNS reagent 2-(<italic>p</italic>-toluidino)naphthalene-6-sulfonic acid was purchased from
Sigma-Aldrich Ireland. The fluorescent dye 1,1&#x02032;-dioctadecyl-3,3,3&#x02032;,3&#x02032;-tetramethylindotricarbocyanine
Iodide (DiR) was purchased from Thermo Fisher Scientific Ireland.
Lipofectamine MessengerMax transfection reagent was purchased from
Fisher Scientific Ireland. Cy5-labeled luciferase mRNA was purchased
from TriLink BioTechnologies.</p></sec><sec id="sec4.2"><title>Instrumentation and Characterization</title><p>Molecular weight
and polydispersity (&#x00110;) of the polymers were determined by gel
permeation chromatography (GPC) using a Tosoh EcoSEC HLC-8320GPC with
a refractive index (RI) detector, conducted in tetrahydrofuran (THF)
mobile phase, calibrated with linear polystyrene standards on a TKSgel
G3000 + 4000HHR column operating at 1.0 mL min<sup>&#x02013;1</sup>. Samples were filtered through 0.45 &#x003bc;m PTFE filters (Fisher
Scientific Ireland) before injection, at an approximately 2 mg mL<sup>&#x02013;1</sup> polymer concentration.</p><p><sup>1</sup>H NMR spectra
were recorded on a Bruker 400 MHz NMR spectrometer in deuterated chloroform
(CDCl<sub>3</sub>, Sigma-Aldrich Ireland), using as internal reference
the residual proton resonance of the solvent peak at 7.26 ppm. <sup>13</sup>C NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer
in deuterated chloroform (CDCl<sub>3</sub>), using the residual proton
resonance of the solvent peak at 77.160 ppm as an internal reference.
Chemical shifts (&#x003b4;) are reported in parts per million (ppm).
Splitting patterns are reported as follows: singlet (s), doublet (d),
triplet (t), quadruplet (q), quintuplet (quint), and multiplet (m).
All NMR spectra were processed using MestReNova NMR software, version
12.0.0&#x02013;20080 (Mestrelab Research S.L.).</p><p>Nominal mass
spectra were recorded on a Waters Quattro Micro triple
quadrupole instrument in electrospray ionization (ESI) mode using
50% acetonitrile&#x02013;water containing 0.1% formic acid as the eluent;
samples were prepared at a concentration of approximately 1 mg mL<sup>&#x02013;1</sup> in water.</p></sec><sec id="sec4.3"><title>Synthesis of the Custom Amino-Alcohols</title><p>The synthesis
of the custom amino alcohols was performed as previously reported
by Kowalski et al.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p><p>As an example,
3,3&#x02032;-diamino-<italic>N</italic>-methyldipropylamine (2.22 mL,
13.8 mmol, 1 equiv) was dissolved in dry MeOH (10 mL). Methyl acrylate
(6.2 mL, 68.9 mmol, 5 equiv) was added to the solution dropwise. The
reaction mixture was stirred at room temperature (RT) under an inert
atmosphere for 2 days. The completion of the reaction was analyzed
by <sup>1</sup>H NMR. The solvent was removed under reduced pressure
and purified by column chromatography in silica gel (pore size of
60 &#x000c5;, 230&#x02013;400 mesh particle size, and 40&#x02013;63 &#x003bc;m
particle size) using DCM/MeOH/NH<sub>4</sub>OH (87.5:11:1.5) as the
mobile phase. The reaction mixture was dissolved in the minimum amount
of mobile phase and added to the column when the silica was compacted.
The collected fractions were checked by thin-layer chromatography
(TLC), and the fractions containing the purified amino-alcohol were
mixed. The solvents were removed under reduced pressure, and the purified
product was taken to the next step. A round-bottomed flask containing
the ester was purged with N<sub>2</sub> and dissolved in anhydrous
THF (12 mL). The reaction flask was cooled to 0 &#x000b0;C, and 1 M LiAlH<sub>4</sub> in THF (Sigma-Aldrich Ireland) (47.7 mL, 1256.1 mmol, 4.2
equiv) was added dropwise. The reaction mixture was equilibrated to
RT overnight. Na<sub>2</sub>SO<sub>4</sub>&#x000b7;10 H<sub>2</sub>O
and 2-methyltetrahydrofuran (10 mL) were added to quench the reaction
and stirred for 30 min until all gray solids turned into a white suspension.
Next, the mixture was filtered using a B&#x000fc;chner funnel with
filter paper (grade 3) covered with anhydrous Na<sub>2</sub>SO<sub>4</sub> to ensure the removal of solids and water. If the filtrate
appeared cloudy, additional drying with Na<sub>2</sub>SO<sub>4</sub> and filtration with a PTFE 0.45 &#x003bc;m filter were performed.
The filtrate was evaporated under reduced pressure to yield the amino-alcohol
AA2 (2.9 g, 76%) as a pale-yellow syrup. AA3, AA4, AA6, and AA7 were
similarly synthesized, and the resulting yields for all the AAs are
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Table S5</ext-link>. All of the synthesized
amino-alcohols were characterized by NMR and ESI (characterization
of amino-alcohols, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">Supporting Information</ext-link>).</p></sec><sec id="sec4.4"><title>Synthesis of Amino-Polyesters (APEs)</title><p>APEs were synthesized
via ring-opening polymerization (ROP) of the different lactones (HL,
NL, DL, JL, DD, and TD) in the presence of an amino-alcohol (AA1,
AA2, AA3, AA4, AA6, AA7) as an initiator and TBD as a catalyst in
bulk at room temperature. The monomer-to-initiator hydroxyl group
ratio was set equal to 3 in order to obtain APEs with 3 units of lactones
for each arm. The hydroxyl group of the initiator-to-catalyst molar
ratio was set to be equal to 10, 6.3, or 4.4, depending on the lactone
used. As an example, for AA1-HL-3, 1.159 g of HL, 0.2 g of AA1, and
24 mg of Na<sub>2</sub>SO<sub>4</sub> anhydrous were poured into a
10 mL vial and left to stir for 15 min. Then, the mixture was poured
into another vial with 47 mg of TBD and 24 mg of Na<sub>2</sub>SO<sub>4</sub> anhydrous and was left to react under vigorous stirring for
24 h at room temperature. The polymerization was stopped by adding
an excess of benzoic acid in dichloromethane or diethyl ether (1 mmol
mL<sup>&#x02013;1</sup>). The final mixture was further diluted in
dichloromethane and washed three times with a saturated solution of
NaCl. The organic phase was recovered, dried with Na<sub>2</sub>SO<sub>4</sub> anhydrous, filtered with a PTFE 0.45 &#x003bc;m filter, and
the solvent was removed under reduced pressure to obtain the purified
APE as a viscous syrup. The final APEs were characterized via GPC
and <sup>1</sup>H NMR (CDCl<sub>3</sub>, Bruker, 400 MHz) before and
after purification.</p></sec><sec id="sec4.5"><title>Differential Scanning Calorimetry (DSC)</title><p>Differential
scanning calorimetry (DSC) was employed to determine the glass transition
temperature (Tg) of the APEs. A DSC Q1000 (TA Instruments) was used,
and the thermograms were analyzed using TA Universal Analysis software.
Weighted samples (3&#x02013;10 mg) were measured in hermetically sealed
pans; after sealing the pans, a hole was made to allow solvent traces
to evaporate. The samples were subjected to 3 heating and cooling
cycles with a ramp from 120 to &#x02212;80 &#x000b0;C at 10 &#x000b0;C min<sup>&#x02013;1</sup>. The first heating cycle was used to evaporate any
traces of the solvent. Tg was determined as the midpoint between the
onset and end of the change in specific heat observed as a shift in
the baseline in the thermogram of a dynamic scan.</p></sec><sec id="sec4.6"><title>mRNA Synthesis
and Characterization</title><p>DNA plasmids containing
a T7 promoter upstream of the sequence encoding for luciferase (FLuc)
were used as templates for mRNA synthesis. The DNA plasmids were linearized
using the restriction enzyme XbaI (New England Biolabs, Ipswich, MA)
and transcribed using the HiScribe T7 RNA Synthesis Kit (New England
Biolabs). To synthesize nucleoside-modified mRNA, uridine triphosphate
was replaced with either 5-methoxyuridine (5moU) triphosphate or N1-methylpseudouridine
(m1&#x003c8;) triphosphate (TriLink, San Diego, CA) in the transcription
reaction. The mRNA was post-transcriptionally capped using the Vaccinia
Capping System (New England Biolabs) and mRNA Cap2&#x02032;-<italic>O</italic>-Methyltransferase (New England Biolabs) resulting in a
Cap1 structure. A poly(A) tail of approximately 120 nucleotides was
added by using <italic>E. coli</italic> Poly(A) Polymerase (New England
Biolabs). All mRNAs were purified using the Monarch RNA Cleanup Kit
(New England Biolabs). RNA concentration was determined using a NanoDrop
One (Thermo Scientific). The final purified mRNAs contained a 5&#x02032;
cap (Cap1), 5&#x02032; and 3&#x02032; UTRs derived from the human hemoglobin
subunit beta (HBB) gene, a coding region as listed below, and a poly(A)tail.
mRNA integrity and purity were characterized by agarose gel electrophoresis
under denaturing conditions (E-Gel 2% EX gels, ThermoFisher). The
gels were imaged using an iBright Imaging System (ThermoFisher).</p><p>FLuc:</p><p>ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGTCCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCCGAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA</p></sec><sec id="sec4.7"><title>Formulation and Characterization of the Nanoparticles</title><p>The
APE lipid nanoparticles (APE-LNPs) were formulated by microfluidics,
mixing ethanol and aqueous phases at a 1:3 volumetric ratio using
syringe pumps (Pump 33 DDS, Harvard Apparatus), as previously described.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> The ethanol phase was prepared by solubilizing
a mixture of ionizable APE, DOPE, cholesterol, and C14-PEG<sub>2000</sub> at a molar ratio of 50:25:23.5:1.5 and A 9:1 nitrogen-to-phosphate
(N/P) ratio. The aqueous phase contained mRNA suspended in 10 mM citrate
buffer at pH 3.2. The APE-LNPs formulated with DOPC and DSPC were
prepared by substituting DOPE. The APE-LNPs labeled with DiR were
formulated as described above, with an ethanol phase composed of APE,
DOPE, cholesterol, DiR, and C14-PEG<sub>2000</sub> at a molar ratio
of 50:25:22.5:1:1.5, and the same aqueous phase composition. The concentration
of mRNA encapsulated into APE nanoparticles was determined by the
Quant-iT RiboGreen assay (ThermoFisher), according to the manufacturer&#x02019;s
protocol. The efficacy of mRNA encapsulation into APE-LNPs was calculated
by comparing measurements in the absence and presence of 1% (v/v)
Triton X-100. Nanoparticle size, polydispersity (PDI), and &#x003b6;-potential
(ZP) were analyzed by dynamic light scattering (DLS) using a Zetasizer
Nano ZS (Malvern Instruments, Worcestershire, UK). APE-LNP hydrodynamic
diameters are reported as the average Z-average of at least two independent
measurements. The stability of the APE-LNPs was evaluated by measuring
the size of the particles stored at 4 &#x000b0;C at days 0, 7, 14, and
28 using DLS, as described above.</p><p>C12&#x02013;200 lipid nanoparticles
were formulated by microfluidics, mixing ethanol and aqueous phases
at a 1:3 volumetric ratio using syringe pumps, as previously described.
The ethanol phase was prepared by solubilizing a mixture of C12&#x02013;200,
DOPE, cholesterol, and C14-PEG<sub>2000</sub> at a molar ratio of
35:16:46.5:2.5 and a 10:1 Nitrogen-to-Phosphate (N/P) ratio. The aqueous
phase contained mRNA suspended in 10 mM citrate buffer at pH 3.2.
The concentration of encapsulated mRNA, as well as the size, PDI,
and ZP, were analyzed as described above.</p><p>MC3 lipid nanoparticles
were formulated by microfluidics, mixing
ethanol and the aqueous phase at a 1:3 volumetric ratio using syringe
pumps, as previously described. The ethanol phase was prepared by
solubilizing a mixture of MC3, DSPC, cholesterol, and DMG-PEG<sub>2000</sub> at a molar ratio of 50:10:38.5:1.5 and a 14:1 nitrogen-to-phosphate
(N/P) ratio. The aqueous phase contained mRNA suspended in 10 mM citrate
buffer at pH 3.2. The concentration of encapsulated mRNA, as well
as the size, PDI, and ZP, were analyzed as described above.</p></sec><sec id="sec4.8"><title>APE-LNP
p<italic>K</italic><sub>a</sub> and Surface Ionization
Measurements</title><p>Nanoparticle surface p<italic>K</italic><sub>a</sub> was determined using the 2-(<italic>p</italic>-toluidino)naphthalene-6-sulfonic
acid (TNS) assay. Briefly, 20 mM citrate, PBS, and ammonium acetate
buffers were prepared and titrated to pH values ranging from 1 to
12 in increments of 0.5. The citrate buffer was used from pH 1 to
6, PBS from pH 6.5 to 7.5, and ammonium acetate from pH 8 to 12. The
pH of the buffers was adjusted using 1 M sodium hydroxide and 1 M
hydrochloric acid. A 300 mM stock of 6-(<italic>p</italic>-toluidino)-2-naphthalenesulfonic
acid sodium salt (TNS reagent) was prepared in DMSO, and APE-LNPs
were diluted to 50 &#x003bc;M total lipids in PBS. 88 &#x003bc;L of buffer,
10 &#x003bc;L of APE-LNPs, and 2 &#x003bc;L of TNS reagent were added
to a black 96-well plate in duplicates. The plate was incubated in
the dark, shaking at 100 rpm for 5 min at room temperature. TNS fluorescence
intensity was measured at &#x003bb;<sub>ex</sub> = 322 nm and &#x003bb;<sub>em</sub> = 431 nm using a Tecan SPARK plate reader (Tecan, Reading,
UK). The APE-LNP surface p<italic>K</italic><sub>a</sub> was determined
to be the pH at which 50% of the amine proportion occurred. All measurements
were performed using a manual gain setting of 45.</p></sec><sec id="sec4.9"><title>Cryogenic Transmission
Electron Microscopy (Cryo-TEM)</title><p>For Cryogenic Transmission
Electron Microscopy (cryo-TEM) samples
(3 &#x003bc;L) were applied to glow-discharged Lacey carbon film on
300 Cooper mesh (Ted Pella 01896-F) and vitrified in liquid ethane
using an FEI Vitrobot Mark IV (Thermo Fisher Scientific) at 4 &#x000b0;C
with 95% humidity, a 4 s blot time, and 0 blot force. Grids were imaged
with a Glacios electron microscope (Thermo Fisher Scientific) operating
at 200 kV and equipped with a Falcon 3EC Direct Electron Detector
at the Centre of New Technologies, University of Warsaw. Images were
recorded in linear mode with a physical pixel size of 1.586 &#x000c5;
(nominal magnification of 92,000x) and a total dose of 27.19 e/&#x000c5;<sup>2</sup>.</p></sec><sec id="sec4.10"><title>Cell Culture</title><p>HeLa cells (provided
by Dr. Krajewska&#x02019;s
lab) were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium
(DMEM) (containing 4500 mg L<sup>&#x02013;1</sup> glucose, <sc>l</sc>-glutamine, sodium pyruvate, and sodium bicarbonate) (Cat No. D6429,
Merck) supplemented with 10% heat-inactivated fetal bovine serum (hiFBS,
Merck) and 1% penicillin/streptomycin (Merck). Cells were passaged
every 3&#x02013;4 days.</p><p>The human monocyte cell line THP-1 was
donated by the Cancer Research @UCC research center, University College
Cork. Cells were cultured in Roswell Park Memorial Institute (RPMI)
medium 1640 (containing 4500 mg L<sup>&#x02013;1</sup><sc>d</sc>-glucose,
2383 mg L<sup>&#x02013;1</sup> HEPES buffer, <sc>l</sc>-glutamine,
110 mg L<sup>&#x02013;1</sup> sodium pyruvate, and 1500 mg L<sup>&#x02013;1</sup> sodium bicarbonate (Cat No. A1049101, Fisher Scientific), supplemented
with 10% hiFBS and 1% penicillin/streptomycin. Cells were passaged
every 2&#x02013;3 days.</p><p>The human umbilical vein endothelial
cells (HUVECs) were purchased
from Lonza Bioscience (Basel, Switzerland). The cells were cultured
in EBM-2 basal medium supplemented with the EGM-2 MV SingleQuots Kit
Supplements &#x00026; Growth Factors (Lonza Bioscience). HUVECs from passages
4 to 6 were used for experiments.</p><p>All cell lines were incubated
in a humidified atmosphere of 5%
CO<sub>2</sub> at 37 &#x000b0;C and routinely tested for the absence
of mycoplasma using the Mycoplasma Detection Kit (Jena Bioscience,
Th&#x000fc;ringen, Germany, Cat No. PP-401).</p></sec><sec id="sec4.11"><title>In Vitro Transfections</title><p>For the APE library screen,
HeLa and HUVEC cells were seeded in white 96-well plates (Costar)
at 10,000 cells per well 1 day before the experiment. THP-1 cells
were seeded in white 96-well plates at 20,000 cells per well and stimulated
with phorbol ester, phorbol-12-myristate-13-acetate (PMA), at a concentration
of 10 ng mL<sup>&#x02013;1</sup> 2 days before the experiment to differentiate
the cells into an M0 phenotype. One day before the experiment, the
media was changed to remove the PMA. APE-LNPs, C12&#x02013;200, and
MC3 nanoparticles containing 50 ng of 5moU-modified FLuc mRNA were
added to each well, and the cells were incubated for 24 h. Cell viability
and FLuc expression were analyzed with CellTiter-Fluor Cell Viability
and One-Glo Luciferase assays (Promega, distributed by MyBio), according
to the manufacturer&#x02019;s protocol. The fluorescence and luminescence
signals were quantified using a Tecan SPARK plate reader (Tecan, Reading,
UK).</p></sec><sec id="sec4.12"><title>Cellular Uptake Analysis</title><p>For the flow cytometry analysis,
HeLa cells were seeded at 30,000 cells/cm<sup>2</sup> into 24-well
plates 1 day before the experiment and incubated for 24 h with the
APE-LNPs containing 250 ng of Cy5-labeled 5moU-modified FLuc mRNA
(TriLink BioTechnologies). Cells were washed with PBS and detached
from the surface using TrypLE Express Enzyme (Thermo Fisher, Ireland),
after which they were immediately transferred to tubes containing
5% FBS in PBS and kept on ice. Next, samples were centrifuged for
5 min at 400<italic>g</italic> at 4 &#x000b0;C, followed by two washing
steps with 5% FBS in PBS and resuspended in 0.2 mL of PBS containing
0.5% paraformaldehyde (PFA) to fix the cells. Samples were analyzed
using a BD FACSCelesta flow cytometer (BD Biosciences), and analysis
was performed with FlowJo v10.4 software.</p><p>For fluorescent microscopy
analysis, HeLa cells were seeded onto cover glasses in a 12-well plate
at 100,000 cells per well 1 day before the experiment. Cells were
incubated for 24 h with the APE-LNPs containing 250 ng of Cy5-labeled
mRNA. Subsequently, the cells were washed with PBS and fixed in 2%
PFA for 20 min. After fixation, the cells were washed and incubated
with 1 &#x003bc;gmL<sup>&#x02013;1</sup> DAPI nuclear stain (Merck) for
15 min. Cover glasses were washed, mounted onto microscope slides,
and stored at 4 &#x000b0;C. Images were captured using a confocal laser
scanning microscope (Olympus FV1000) fitted with 405 and 633 nm lasers,
and a 60x dry objective lens. All images were acquired in the linear
range, avoiding local saturation, at an image resolution of 1024 &#x000d7;
1024 pixels and with a pinhole size of 1 Airy unit. Images were analyzed
and processed using ImageJ v2.14.0 software.</p></sec><sec id="sec4.13"><title>Animal Studies</title><p>C57BL/6 mice were provided by Envigo
RMS (UK). All animals were housed and cared for in compliance with
protocols and procedures approved by the Animal Experimentation Ethics
Committee of University College Cork and the Health Products Regulatory
Authority (HPRA) (Project Authorization Number: AE19130/P164). For
mRNA delivery studies, selected APE-LNPs containing 5moU-modified
FLuc mRNA were injected intravenously into female C57BL/6 mice (18&#x02013;22
g) via the tail vein (0.5 mg kg<sup>&#x02013;1</sup>). After 6 h of
the injection, <sc>d</sc>-Luciferin Potassium (PerkinElmer) at a concentration
of 30 mg/mL was injected intraperitoneally, and the mice were euthanized
10 min later. The organs were extracted and imaged using an IVIS Lumina
Series III In Vivo Imaging System (PerkinElmer). The luminescence
signals were quantified using Living Image software v4.5.2 (PerkinElmer).</p><p>For biodistribution studies, APE-LNPs labeled with DiR dye were
injected intravenously into female C57BL/6 mice (18&#x02013;22 g) via
the tail vein (0.5 mg kg<sup>&#x02013;1</sup>). After 6 h of the injection,
the mice were euthanized, and the organs were extracted and imaged
using the IVIS Lumina Series III In Vivo Imaging System (PerkinElmer).
The fluorescence signals were quantified using Living Image software
v4.5.2 (PerkinElmer).</p></sec><sec id="sec4.14"><title>Statistical Analysis</title><p>All data were
analyzed with GraphPad
Prism 9 (La Jolla, CA, USA) and are presented as mean &#x000b1; SD. Statistical
analysis was performed by using one-way ANOVA followed by Tukey&#x02019;s
or Dunnett&#x02019;s multiple comparisons test to compare multiple
replicate means, or an unpaired two-tailed Student&#x02019;s <italic>t</italic>-test assuming equal variances to compare two replicate
means. Differences were considered significant when <italic>p</italic> &#x02264; 0.05. Correlation analysis to assess the relationship between
the hydrodynamic diameter, surface charge, or mRNA encapsulation efficacy
and the lactone side chain length was determined by computing a two-tailed
nonparametric Spearman correlation with a 95% confidence interval.
A correlation coefficient (&#x003c1;) of &#x003c1; = 1 indicates a perfect
positive correlation between the variables, &#x003c1; = &#x02212;1 indicates
a perfect negative correlation between the variables, and &#x003c1;
= 0 indicates no correlation between the variables.</p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting
Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsabm.5c00116?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsabm.5c00116</ext-link>.<list id="silist1" list-type="simple"><list-item><p>Polymer characterization
(1H-NMR, GPC, and DSC spectra)
and additional nanoparticle characterization of APE-LNP formulations
(including formulation composition, size, polydispersity, surface
charge, p<italic>K</italic><sub>a</sub>, encapsulation efficiency,
nanoparticle uptake, mRNA delivery efficacy, biodistribution, and
stability) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsabm.5c00116/suppl_file/mt5c00116_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mt5c00116_si_001.pdf"><caption><p>mt5c00116_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p><sup>#</sup> A.L.E. and L.M.M. contributed equally to this work,
designed and
executed experiments and wrote the manuscript. A.L.E. contributed
chemistry expertise for the design and synthesis of the polymers.
L.M.M. contributed molecular biology expertise for mRNA design and
synthesis. M.E. and Z.K. assisted with the experiments, M.C.C. was
responsible for cryo-TEM image acquisition, M.R.A. assisted with the
acquisition of confocal images, S.V. contributed to study design and
edited the manuscript, and P.S.K. guided the study, assisted with
the experimental work, and wrote the manuscript.</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare the following competing financial interest(s): Conflict of
Interest: P.S. Kowalski, A.L. Espinar, and L. M. Mulder filed a patent
for the development of the described amino-polyesters for drug delivery.
The remaining authors declare no competing interests.</p></notes><ack><title>Acknowledgments</title><p>The authors thank Dr. Tomasz G&#x000f3;ral and the
Cryomicroscopy and Electron Diffraction Core Facility at the Centre
of New Technologies, University of Warsaw, for help with cryo-TEM
image acquisition, and Prof. Catriona O&#x02019;Driscoll for proofreading
the manuscript. P.S.K. acknowledges support from the Health Research
Board, Grant number EIA-2019-006; European Research Council, Grant
number 101041424 &#x02013; CIRCLE; and Horizon Europe, Grant number
101057491 &#x02013; GENEGUT. L.M.M. acknowledges support from the Irish
Research Council Government of Ireland Postgraduate Scholarship, Grant
number GOIPG/2021/1649. For the purpose of Open Access, the author
has applied a CC BY public copyright license to any Author Accepted
Manuscript version arising from this submission.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Kowalski</surname><given-names>P. S.</given-names></name>; <name><surname>Rudra</surname><given-names>A.</given-names></name>; <name><surname>Miao</surname><given-names>L.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Delivering the Messenger:
Advances in Technologies for Therapeutic mRNA Delivery</article-title>. <source>Mol. Ther.</source>
<year>2019</year>, <volume>27</volume>, <fpage>710</fpage>&#x02013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id>.<pub-id pub-id-type="pmid">30846391</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Xiong</surname><given-names>Q.</given-names></name>; <name><surname>Lee</surname><given-names>G. Y.</given-names></name>; <name><surname>Ding</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Shi</surname><given-names>J.</given-names></name>
<article-title>Biomedical
Applications of mRNA Nanomedicine</article-title>. <source>Nano Res.</source>
<year>2018</year>, <volume>11</volume>, <fpage>5281</fpage>&#x02013;<lpage>5309</lpage>. <pub-id pub-id-type="doi">10.1007/s12274-018-2146-1</pub-id>.<pub-id pub-id-type="pmid">31007865</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Polack</surname><given-names>F. P.</given-names></name>; <name><surname>Thomas</surname><given-names>S. J.</given-names></name>; <name><surname>Kitchin</surname><given-names>N.</given-names></name>; <name><surname>Absalon</surname><given-names>J.</given-names></name>; <name><surname>Gurtman</surname><given-names>A.</given-names></name>; <name><surname>Lockhart</surname><given-names>S.</given-names></name>; <name><surname>Perez</surname><given-names>J. L.</given-names></name>; <name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>; <name><surname>Moreira</surname><given-names>E. D.</given-names></name>; <name><surname>Zerbini</surname><given-names>C.</given-names></name>; et al. <article-title>Safety
and Efficacy
of the BNT162b2 mRNA COVID-19 Vaccine</article-title>. <source>N. Engl.
J. Med.</source>
<year>2020</year>, <volume>383</volume> (<issue>27</issue>), <fpage>2603</fpage>&#x02013;<lpage>2615</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>.<pub-id pub-id-type="pmid">33301246</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Baden</surname><given-names>L. R.</given-names></name>; <name><surname>El Sahly</surname><given-names>H. M.</given-names></name>; <name><surname>Essink</surname><given-names>B.</given-names></name>; <name><surname>Kotloff</surname><given-names>K.</given-names></name>; <name><surname>Frey</surname><given-names>S.</given-names></name>; <name><surname>Novak</surname><given-names>R.</given-names></name>; <name><surname>Diemert</surname><given-names>D.</given-names></name>; <name><surname>Spector</surname><given-names>S. A.</given-names></name>; <name><surname>Rouphael</surname><given-names>N.</given-names></name>; <name><surname>Creech</surname><given-names>C. B.</given-names></name>; et al. <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2
Vaccine</article-title>. <source>N. Engl. J. Med.</source>
<year>2021</year>, <volume>384</volume>, <fpage>403</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id>.<pub-id pub-id-type="pmid">33378609</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Parhiz</surname><given-names>H.</given-names></name>; <name><surname>Atochina-Vasserman</surname><given-names>E. N.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>
<article-title>mRNA-Based Therapeutics:
Looking beyond COVID-19 Vaccines</article-title>. <source>Lancet</source>
<year>2024</year>, <volume>403</volume>, <fpage>1192</fpage>&#x02013;<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(23)02444-3</pub-id>.<pub-id pub-id-type="pmid">38461842</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Hou</surname><given-names>X.</given-names></name>; <name><surname>Zaks</surname><given-names>T.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Dong</surname><given-names>Y.</given-names></name>
<article-title>Lipid Nanoparticles
for mRNA Delivery</article-title>. <source>Nat. Rev. Mater.</source>
<year>2021</year>, <volume>6</volume>, <fpage>1078</fpage>&#x02013;<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id>.<pub-id pub-id-type="pmid">34394960</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Di</surname><given-names>J.</given-names></name>; <name><surname>Du</surname><given-names>Z.</given-names></name>; <name><surname>Wu</surname><given-names>K.</given-names></name>; <name><surname>Jin</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>
<article-title>Biodistribution and
Non-Linear Gene Expression of mRNA LNPs Affected
by Delivery Route and Particle Size</article-title>. <source>Pharm.
Res.</source>
<year>2022</year>, <volume>39</volume>, <fpage>105</fpage>&#x02013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-022-03166-5</pub-id>.<pub-id pub-id-type="pmid">35080707</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Hassett</surname><given-names>K. J.</given-names></name>; <name><surname>Rajlic</surname><given-names>I. L.</given-names></name>; <name><surname>Bahl</surname><given-names>K.</given-names></name>; <name><surname>White</surname><given-names>R.</given-names></name>; <name><surname>Cowens</surname><given-names>K.</given-names></name>; <name><surname>Jacquinet</surname><given-names>E.</given-names></name>; <name><surname>Burke</surname><given-names>K. E.</given-names></name>
<article-title>mRNA Vaccine Trafficking and Resulting
Protein Expression after Intramuscular Administration</article-title>. <source>Mol. Ther. Nucleic Acids.</source>
<year>2024</year>, <volume>35</volume>, <fpage>102083</fpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.102083</pub-id>.<pub-id pub-id-type="pmid">38161733</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>; <name><surname>Varley</surname><given-names>A. J.</given-names></name>; <name><surname>Golubovic</surname><given-names>A.</given-names></name>; <name><surname>Ze Lu</surname><given-names>R. X.</given-names></name>; <name><surname>Wang</surname><given-names>K. C.</given-names></name>; <name><surname>Yeganeh</surname><given-names>M.</given-names></name>; <name><surname>Vosoughi</surname><given-names>D.</given-names></name>; et al. <article-title>Combinatorial Design
of Ionizable Lipid Nanoparticles for Muscle-Selective
mRNA Delivery with Minimized off-Target Effects</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2023</year>, <volume>120</volume> (<issue>50</issue>), <elocation-id>e2309472120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2309472120</pub-id>.<pub-id pub-id-type="pmid">38060560</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Cheng</surname><given-names>Q.</given-names></name>; <name><surname>Wei</surname><given-names>T.</given-names></name>; <name><surname>Farbiak</surname><given-names>L.</given-names></name>; <name><surname>Johnson</surname><given-names>L. T.</given-names></name>; <name><surname>Dilliard</surname><given-names>S. A.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>Selective
Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery
and CRISPR&#x02013;Cas Gene Editing</article-title>. <source>Nat. Nanotechnol.</source>
<year>2020</year>, <volume>15</volume>, <fpage>313</fpage>&#x02013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-020-0669-6</pub-id>.<pub-id pub-id-type="pmid">32251383</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Dilliard</surname><given-names>S. A.</given-names></name>; <name><surname>Cheng</surname><given-names>Q.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>On the
Mechanism of Tissue-Specific
mRNA Delivery by Selective Organ Targeting Nanoparticles</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2021</year>, <volume>118</volume> (<issue>52</issue>), <elocation-id>e2109256118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2109256118</pub-id>.<pub-id pub-id-type="pmid">34933999</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Omo-Lamai</surname><given-names>S.</given-names></name>; <name><surname>Zamora</surname><given-names>M. E.</given-names></name>; <name><surname>Patel</surname><given-names>M. N.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Nong</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Peshkova</surname><given-names>A.</given-names></name>; <name><surname>Majumder</surname><given-names>A.</given-names></name>; <name><surname>Melamed</surname><given-names>J. R.</given-names></name>; <name><surname>Chase</surname><given-names>L. S.</given-names></name>; et al. <article-title>Physicochemical Targeting
of Lipid Nanoparticles
to the Lungs Induces Clotting: Mechanisms and Solutions</article-title>. <source>Adv. Mater.</source>
<year>2024</year>, <volume>36</volume> (<issue>26</issue>), <elocation-id>e2312026</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202312026</pub-id>.<pub-id pub-id-type="pmid">38394670</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Omo-Lamai</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Patel</surname><given-names>M. N.</given-names></name>; <name><surname>Essien</surname><given-names>E.-O.</given-names></name>; <name><surname>Shen</surname><given-names>M.</given-names></name>; <name><surname>Majumdar</surname><given-names>A.</given-names></name>; <name><surname>Espy</surname><given-names>C.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Channer</surname><given-names>B.</given-names></name>; <name><surname>Tobin</surname><given-names>M.</given-names></name>; et al. <article-title>Lipid Nanoparticle-Associated Inflammation Is Triggered
by Sensing of Endosomal Damage: Engineering Endosomal Escape Without
Side Effects</article-title>. <source>bioRxiv, Preprint.</source>
<year>2024</year>, <fpage>2024</fpage><pub-id pub-id-type="doi">10.1101/2024.04.16.589801</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Friesen</surname><given-names>J. J.</given-names></name>; <name><surname>Blakney</surname><given-names>A. K.</given-names></name>
<article-title>Trends in the Synthetic
Polymer Delivery of RNA</article-title>. <source>J. Gene Med.</source>
<year>2024</year>, <volume>26</volume> (<issue>2</issue>), <elocation-id>e3672</elocation-id><pub-id pub-id-type="doi">10.1002/jgm.3672</pub-id>.<pub-id pub-id-type="pmid">38380796</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Mixich</surname><given-names>L.</given-names></name>; <name><surname>Boonstra</surname><given-names>E.</given-names></name>; <name><surname>Cabral</surname><given-names>H.</given-names></name>
<article-title>Polymer-Based mRNA
Delivery Strategies for Advanced Therapies</article-title>. <source>Adv. Healthcare Mater.</source>
<year>2023</year>, <volume>12</volume> (<issue>15</issue>), <elocation-id>e2202688</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202202688</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Yousefi
Adlsadabad</surname><given-names>S.</given-names></name>; <name><surname>Hanrahan</surname><given-names>J. W.</given-names></name>; <name><surname>Kakkar</surname><given-names>A.</given-names></name>
<article-title>mRNA Delivery: Challenges
and Advances through Polymeric Soft Nanoparticles</article-title>. <source>Int. J. Mol. Sci.</source>
<year>2024</year>, <volume>25</volume>, <fpage>1739</fpage><pub-id pub-id-type="doi">10.3390/ijms25031739</pub-id>.<pub-id pub-id-type="pmid">38339015</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Lai</surname><given-names>W. F.</given-names></name>; <name><surname>Wong</surname><given-names>W. T.</given-names></name>
<article-title>Design
of Polymeric Gene Carriers for Effective Intracellular
Delivery</article-title>. <source>Trends Biotechnol.</source>
<year>2018</year>, <volume>36</volume>, <fpage>713</fpage>&#x02013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2018.02.006</pub-id>.<pub-id pub-id-type="pmid">29525137</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Kamaly</surname><given-names>N.</given-names></name>; <name><surname>Yameen</surname><given-names>B.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Farokhzad</surname><given-names>O. C.</given-names></name>
<article-title>Degradable
Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms
of Controlling Drug Release</article-title>. <source>Chem. Rev.</source>
<year>2016</year>, <volume>116</volume>, <fpage>2602</fpage>&#x02013;<lpage>2663</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00346</pub-id>.<pub-id pub-id-type="pmid">26854975</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Piotrowski-Daspit</surname><given-names>A.
S.</given-names></name>; <name><surname>Kauffman</surname><given-names>A. C.</given-names></name>; <name><surname>Bracaglia</surname><given-names>L. G.</given-names></name>; <name><surname>Saltzman</surname><given-names>W. M.</given-names></name>
<article-title>Polymeric Vehicles
for Nucleic Acid Delivery</article-title>. <source>Adv. Drug Delivery
Rev.</source>
<year>2020</year>, <volume>156</volume>, <fpage>119</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.06.014</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>El-Say</surname><given-names>K. M.</given-names></name>; <name><surname>El-Sawy</surname><given-names>H. S.</given-names></name>
<article-title>Polymeric Nanoparticles: Promising Platform for Drug
Delivery</article-title>. <source>Int. J. Pharm.</source>
<year>2017</year>, <volume>528</volume>, <fpage>675</fpage>&#x02013;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.06.052</pub-id>.<pub-id pub-id-type="pmid">28629982</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Ma</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>D.</given-names></name>
<article-title>Polyester Materials for mRNA Delivery</article-title>. <source>Explor
Target Antitumor Ther.</source>
<year>2022</year>, <volume>3</volume>, <fpage>117</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.37349/etat.2022.00075</pub-id>.<pub-id pub-id-type="pmid">36046844</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Wei</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>L.</given-names></name>; <name><surname>Lu</surname><given-names>Q.</given-names></name>; <name><surname>Li</surname><given-names>G.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>
<article-title>Recent Progress and Applications
of Poly(Beta Amino Esters)-Based
Biomaterials</article-title>. <source>J. Controlled Release.</source>
<year>2023</year>, <volume>354</volume>, <fpage>337</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.01.002</pub-id>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Benner</surname><given-names>N. L.</given-names></name>; <name><surname>McClellan</surname><given-names>R. L.</given-names></name>; <name><surname>Turlington</surname><given-names>C. R.</given-names></name>; <name><surname>Haabeth</surname><given-names>O. A. W.</given-names></name>; <name><surname>Waymouth</surname><given-names>R. M.</given-names></name>; <name><surname>Wender</surname><given-names>P. A.</given-names></name>
<article-title>Oligo(Serine
Ester) Charge-Altering Releasable Transporters:
Organocatalytic Ring-Opening Polymerization and Their Use for in Vitro
and in Vivo mRNA Delivery</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2019</year>, <volume>141</volume>, <fpage>8416</fpage>&#x02013;<lpage>8421</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b03154</pub-id>.<pub-id pub-id-type="pmid">31083999</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Hadjichristidis</surname><given-names>N.</given-names></name>
<article-title>Poly(Amino
Ester)s as an Emerging
Synthetic Biodegradable Polymer Platform: Recent Developments and
Future Trends</article-title>. <source>Prog. Polym. Sci.</source>
<year>2023</year>, <volume>136</volume>, <fpage>101634</fpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2022.101634</pub-id>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Kowalski</surname><given-names>P. S.</given-names></name>; <name><surname>Capasso Palmiero</surname><given-names>U.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Rudra</surname><given-names>A.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Ionizable
Amino-Polyesters Synthesized via Ring Opening
Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA
Delivery</article-title>. <source>Adv. Mater.</source>
<year>2018</year>, <volume>30</volume> (<issue>34</issue>), <elocation-id>e1801151</elocation-id><pub-id pub-id-type="doi">10.1002/adma.201801151</pub-id>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="book" id="cit26"><collab>Food and Drug Administration (FDA)</collab>. <source>CFR Code of
Federal Regulations Title 21</source>;<publisher-name>Food and Drug
Administration (FDA)</publisher-name>, <year>2024</year></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Capasso
Palmiero</surname><given-names>U.</given-names></name>; <name><surname>Kaczmarek</surname><given-names>J. C.</given-names></name>; <name><surname>Fenton</surname><given-names>O. S.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Poly(&#x003b2;-Amino
Ester)-Co-Poly(Caprolactone) Terpolymers as Nonviral Vectors for mRNA
Delivery In Vitro and In Vivo</article-title>. <source>Adv. Healthcare
Mater.</source>
<year>2018</year>, <volume>7</volume> (<issue>14</issue>), <elocation-id>e1800249</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.201800249</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Maisha</surname><given-names>N.</given-names></name>; <name><surname>Kulkarni</surname><given-names>C.</given-names></name>; <name><surname>Pandala</surname><given-names>N.</given-names></name>; <name><surname>Zilberberg</surname><given-names>R.</given-names></name>; <name><surname>Schaub</surname><given-names>L.</given-names></name>; <name><surname>Neidert</surname><given-names>L.</given-names></name>; <name><surname>Glaser</surname><given-names>J.</given-names></name>; <name><surname>Cannon</surname><given-names>J.</given-names></name>; <name><surname>Janeja</surname><given-names>V.</given-names></name>; <name><surname>Lavik</surname><given-names>E. B.</given-names></name>
<article-title>PEGylated Polyester Nanoparticles
Trigger Adverse Events in a Large Animal Model of Trauma and in Na&#x000ef;ve
Animals: Understanding Cytokine and Cellular Correlations with These
Events</article-title>. <source>ACS Nano</source>
<year>2022</year>, <volume>16</volume>, <fpage>10566</fpage>&#x02013;<lpage>10580</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c01993</pub-id>.<pub-id pub-id-type="pmid">35822898</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Abd
Elwakil</surname><given-names>M. M.</given-names></name>; <name><surname>Gao</surname><given-names>T.</given-names></name>; <name><surname>Isono</surname><given-names>T.</given-names></name>; <name><surname>Sato</surname><given-names>Y.</given-names></name>; <name><surname>Elewa</surname><given-names>Y. H. A.</given-names></name>; <name><surname>Satoh</surname><given-names>T.</given-names></name>; <name><surname>Harashima</surname><given-names>H.</given-names></name>
<article-title>Engineered
&#x003f5;-Decalactone Lipomers Bypass the Liver to Selectively: In Vivo
Deliver mRNA to the Lungs without Targeting Ligands</article-title>. <source>Mater. Horiz.</source>
<year>2021</year>, <volume>8</volume>, <fpage>2251</fpage>&#x02013;<lpage>2259</lpage>. <pub-id pub-id-type="doi">10.1039/D1MH00185J</pub-id>.<pub-id pub-id-type="pmid">34846429</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Mrksich</surname><given-names>K.</given-names></name>; <name><surname>Padilla</surname><given-names>M. S.</given-names></name>; <name><surname>Joseph</surname><given-names>R. A.</given-names></name>; <name><surname>Han</surname><given-names>E. L.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Palanki</surname><given-names>R.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Mitchell</surname><given-names>M. J.</given-names></name>
<article-title>Influence of Ionizable
Lipid Tail Length on Lipid Nanoparticle Delivery of mRNA of Varying
Length</article-title>. <source>J. Biomed Mater. Res. A</source>
<year>2024</year>, <volume>112</volume>, <fpage>1494</fpage>&#x02013;<lpage>1505</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.a.37705</pub-id>.<pub-id pub-id-type="pmid">38487970</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Lee</surname><given-names>S. M.</given-names></name>; <name><surname>Cheng</surname><given-names>Q.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Johnson</surname><given-names>L. T.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>A Systematic Study of Unsaturation
in Lipid Nanoparticles
Leads to Improved mRNA Transfection In Vivo</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2021</year>, <volume>60</volume>, <fpage>5848</fpage>&#x02013;<lpage>5853</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202013927</pub-id>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Fenton</surname><given-names>O. S.</given-names></name>; <name><surname>Kauffman</surname><given-names>K. J.</given-names></name>; <name><surname>McClellan</surname><given-names>R. L.</given-names></name>; <name><surname>Kaczmarek</surname><given-names>J. C.</given-names></name>; <name><surname>Zeng</surname><given-names>M. D.</given-names></name>; <name><surname>Andresen</surname><given-names>J. L.</given-names></name>; <name><surname>Rhym</surname><given-names>L. H.</given-names></name>; <name><surname>Heartlein</surname><given-names>M. W.</given-names></name>; <name><surname>DeRosa</surname><given-names>F.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Customizable Lipid Nanoparticle Materials
for the Delivery of SiRNAs and MRNAs</article-title>. <source>Angew.
Chem., Int. Ed.</source>
<year>2018</year>, <volume>130</volume>, <fpage>13770</fpage>&#x02013;<lpage>13774</lpage>. <pub-id pub-id-type="doi">10.1002/ange.201809056</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="book" id="cit33"><person-group person-group-type="allauthors"><name><surname>Malcolm</surname><given-names>P.</given-names></name></person-group><source>Stevens Polymer Chemistry:
An IntroductionStevens Polymer Chemistry: An Introduction</source>; <publisher-name>Oxford University Press</publisher-name>: <publisher-loc>New York</publisher-loc>, <year>1999</year>; pp. <fpage>70</fpage>&#x02013;<lpage>74</lpage>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>McEnnis</surname><given-names>K.</given-names></name>
<article-title>Glass Transition Temperature
of PLGA Particles and
the Influence on Drug Delivery Applications</article-title>. <source>Polymers</source>
<year>2022</year>, <volume>14</volume>, <fpage>993</fpage><pub-id pub-id-type="doi">10.3390/polym14050993</pub-id>.<pub-id pub-id-type="pmid">35267816</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Xie</surname><given-names>R.</given-names></name>; <name><surname>Weisen</surname><given-names>A. R.</given-names></name>; <name><surname>Lee</surname><given-names>Y.</given-names></name>; <name><surname>Aplan</surname><given-names>M. A.</given-names></name>; <name><surname>Fenton</surname><given-names>A. M.</given-names></name>; <name><surname>Masucci</surname><given-names>A. E.</given-names></name>; <name><surname>Kempe</surname><given-names>F.</given-names></name>; <name><surname>Sommer</surname><given-names>M.</given-names></name>; <name><surname>Pester</surname><given-names>C. W.</given-names></name>; <name><surname>Colby</surname><given-names>R. H.</given-names></name>; et al. <article-title>Glass
Transition Temperature from the Chemical
Structure of Conjugated Polymers</article-title>. <source>Nat. Commun.</source>
<year>2020</year>, <volume>11</volume> (<issue>1</issue>), <fpage>893</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14656-8</pub-id>.<pub-id pub-id-type="pmid">32060331</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Kaczmarek</surname><given-names>J. C.</given-names></name>; <name><surname>Patel</surname><given-names>A. K.</given-names></name>; <name><surname>Rhym</surname><given-names>L. H.</given-names></name>; <name><surname>Palmiero</surname><given-names>U. C.</given-names></name>; <name><surname>Bhat</surname><given-names>B.</given-names></name>; <name><surname>Heartlein</surname><given-names>M. W.</given-names></name>; <name><surname>DeRosa</surname><given-names>F.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Systemic Delivery
of mRNA and DNA to the Lung Using Polymer-Lipid Nanoparticles</article-title>. <source>Biomaterials</source>
<year>2021</year>, <volume>275</volume>, <fpage>120966</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120966</pub-id>.<pub-id pub-id-type="pmid">34147715</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Mukherjee</surname><given-names>A.</given-names></name>; <name><surname>Waters</surname><given-names>A. K.</given-names></name>; <name><surname>Kalyan</surname><given-names>P.</given-names></name>; <name><surname>Achrol</surname><given-names>A. S.</given-names></name>; <name><surname>Kesari</surname><given-names>S.</given-names></name>; <name><surname>Yenugonda</surname><given-names>V. M.</given-names></name>
<article-title>Lipid-Polymer Hybrid Nanoparticles as a Next-Generation
Drug Delivery Platform: State of the Art, Emerging Technologies, and
Perspectives</article-title>. <source>Int. J. Nanomed.</source>
<year>2019</year>, <volume>14</volume>, <fpage>1937</fpage>&#x02013;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S198353</pub-id>.</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Jain</surname><given-names>T.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Joy</surname><given-names>A.</given-names></name>
<article-title>Structural Insight
into the Viscoelastic Behaviour of Elastomeric Polyesters: Effect
of the Nature of Fatty Acid Side Chains and the Degree of Unsaturation</article-title>. <source>Polym. Chem.</source>
<year>2020</year>, <volume>11</volume>, <fpage>5216</fpage>&#x02013;<lpage>5224</lpage>. <pub-id pub-id-type="doi">10.1039/D0PY00457J</pub-id>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Fenton</surname><given-names>O. S.</given-names></name>; <name><surname>Kauffman</surname><given-names>K. J.</given-names></name>; <name><surname>McClellan</surname><given-names>R. L.</given-names></name>; <name><surname>Appel</surname><given-names>E. A.</given-names></name>; <name><surname>Dorkin</surname><given-names>J. R.</given-names></name>; <name><surname>Tibbitt</surname><given-names>M. W.</given-names></name>; <name><surname>Heartlein</surname><given-names>M. W.</given-names></name>; <name><surname>De Rosa</surname><given-names>F.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials
for Highly Potent in Vivo mRNA Delivery</article-title>. <source>Adv.
Mater.</source>
<year>2016</year>, <volume>28</volume>, <fpage>2939</fpage>&#x02013;<lpage>2943</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201505822</pub-id>.<pub-id pub-id-type="pmid">26889757</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Hao</surname><given-names>J.</given-names></name>; <name><surname>Kos</surname><given-names>P.</given-names></name>; <name><surname>Zhou</surname><given-names>K.</given-names></name>; <name><surname>Miller</surname><given-names>J. B.</given-names></name>; <name><surname>Xue</surname><given-names>L.</given-names></name>; <name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Xiong</surname><given-names>H.</given-names></name>; <name><surname>Elkassih</surname><given-names>S.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>Rapid Synthesis
of a Lipocationic Polyester Library via Ring-Opening Polymerization
of Functional Valerolactones for Efficacious siRNA Delivery</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2015</year>, <volume>137</volume>, <fpage>9206</fpage>&#x02013;<lpage>9209</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.5b03429</pub-id>.<pub-id pub-id-type="pmid">26166403</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Witzigmann</surname><given-names>D.</given-names></name>; <name><surname>Kulkarni</surname><given-names>J. A.</given-names></name>; <name><surname>Leung</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>Cullis</surname><given-names>P. R.</given-names></name>; <name><surname>van der Meel</surname><given-names>R.</given-names></name>
<article-title>Lipid Nanoparticle Technology for Therapeutic Gene
Regulation in the Liver</article-title>. <source>Adv. Drug Delivery
Rev.</source>
<year>2020</year>, <volume>159</volume>, <fpage>344</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.06.026</pub-id>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Hajj</surname><given-names>K. A.</given-names></name>; <name><surname>Ball</surname><given-names>R. L.</given-names></name>; <name><surname>Deluty</surname><given-names>S. B.</given-names></name>; <name><surname>Singh</surname><given-names>S. R.</given-names></name>; <name><surname>Strelkova</surname><given-names>D.</given-names></name>; <name><surname>Knapp</surname><given-names>C. M.</given-names></name>; <name><surname>Whitehead</surname><given-names>K. A.</given-names></name>
<article-title>Branched-Tail Lipid Nanoparticles
Potently Deliver mRNA In Vivo Due to Enhanced Ionization at Endosomal
pH</article-title>. <source>Small</source>
<year>2019</year>, <volume>15</volume> (<issue>6</issue>), <elocation-id>e1805097</elocation-id><pub-id pub-id-type="doi">10.1002/smll.201805097</pub-id>.<pub-id pub-id-type="pmid">30637934</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Yong</surname><given-names>H.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Huang</surname><given-names>D.</given-names></name>; <name><surname>Zhou</surname><given-names>D.</given-names></name>
<article-title>Enhancing Gene Transfection of Poly(&#x003b2;-Amino
Ester)s through Modulation of Amphiphilicity and Chain Sequence</article-title>. <source>J. Controlled Release.</source>
<year>2024</year>, <volume>368</volume>, <fpage>131</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2024.02.002</pub-id>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>van Putten</surname><given-names>R. J.</given-names></name>; <name><surname>Tietema</surname><given-names>A.</given-names></name>; <name><surname>Parsons</surname><given-names>J. R.</given-names></name>; <name><surname>Gruter</surname><given-names>G. J. M.</given-names></name>
<article-title>Polyester
Biodegradability: Importance and Potential for Optimisation</article-title>. <source>Green Chem.</source>
<year>2024</year>, <volume>26</volume>, <fpage>3698</fpage>&#x02013;<lpage>3716</lpage>. <pub-id pub-id-type="doi">10.1039/D3GC04489K</pub-id>.<pub-id pub-id-type="pmid">38571729</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Huang</surname><given-names>P.</given-names></name>; <name><surname>Deng</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>
<article-title>The Roles of Polymers
in mRNA Delivery</article-title>. <source>Matter</source>
<year>2022</year>, <volume>5</volume>, <fpage>1670</fpage>&#x02013;<lpage>1699</lpage>. <pub-id pub-id-type="doi">10.1016/j.matt.2022.03.006</pub-id>.</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Kaczmarek</surname><given-names>J. C.</given-names></name>; <name><surname>Patel</surname><given-names>A. K.</given-names></name>; <name><surname>Kauffman</surname><given-names>K. J.</given-names></name>; <name><surname>Fenton</surname><given-names>O. S.</given-names></name>; <name><surname>Webber</surname><given-names>M. J.</given-names></name>; <name><surname>Heartlein</surname><given-names>M. W.</given-names></name>; <name><surname>DeRosa</surname><given-names>F.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Polymer&#x02013;Lipid
Nanoparticles for Systemic Delivery of mRNA to the Lungs</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2016</year>, <volume>55</volume>, <fpage>13808</fpage>&#x02013;<lpage>13812</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201608450</pub-id>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Mendon&#x000e7;a</surname><given-names>M. C. P.</given-names></name>; <name><surname>Kont</surname><given-names>A.</given-names></name>; <name><surname>Kowalski</surname><given-names>P. S.</given-names></name>; <name><surname>O&#x02019;Driscoll</surname><given-names>C. M.</given-names></name>
<article-title>Design
of Lipid-Based Nanoparticles for Delivery of Therapeutic Nucleic Acids</article-title>. <source>Drug Discov. Today</source>
<year>2023</year>, <volume>28</volume>, <fpage>103505</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103505</pub-id>.<pub-id pub-id-type="pmid">36708760</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Hald
Albertsen</surname><given-names>C.</given-names></name>; <name><surname>Kulkarni</surname><given-names>J. A.</given-names></name>; <name><surname>Witzigmann</surname><given-names>D.</given-names></name>; <name><surname>Lind</surname><given-names>M.</given-names></name>; <name><surname>Petersson</surname><given-names>K.</given-names></name>; <name><surname>Simonsen</surname><given-names>J. B.</given-names></name>
<article-title>The Role of Lipid
Components in Lipid Nanoparticles for Vaccines and Gene Therapy</article-title>. <source>Adv. Drug Delivery Rev.</source>
<year>2022</year>, <volume>188</volume>, <fpage>114416</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2022.114416</pub-id>.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Palanki</surname><given-names>R.</given-names></name>; <name><surname>Han</surname><given-names>E. L.</given-names></name>; <name><surname>Murray</surname><given-names>A. M.</given-names></name>; <name><surname>Maganti</surname><given-names>R.</given-names></name>; <name><surname>Tang</surname><given-names>S.</given-names></name>; <name><surname>Swingle</surname><given-names>K. L.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Yamagata</surname><given-names>H.</given-names></name>; <name><surname>Safford</surname><given-names>H. C.</given-names></name>; <name><surname>Mrksich</surname><given-names>K.</given-names></name>; <name><surname>Peranteau</surname><given-names>W. H.</given-names></name>; <name><surname>Mitchell</surname><given-names>M. J.</given-names></name>
<article-title>Optimized Microfluidic
Formulation and Organic Excipients for Improved Lipid Nanoparticle
Mediated Genome Editing</article-title>. <source>Lab Chip.</source>
<year>2024</year>, <volume>24</volume>, <fpage>3790</fpage>&#x02013;<lpage>3801</lpage>. <pub-id pub-id-type="doi">10.1039/D4LC00283K</pub-id>.<pub-id pub-id-type="pmid">39037068</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>&#x000c1;lvarez-Benedicto</surname><given-names>E.</given-names></name>; <name><surname>Farbiak</surname><given-names>L.</given-names></name>; <name><surname>M&#x000e1;rquez Ram&#x000ed;rez</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Johnson</surname><given-names>L. T.</given-names></name>; <name><surname>Mian</surname><given-names>O.</given-names></name>; <name><surname>Guerrero</surname><given-names>E. D.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>Optimization of
Phospholipid Chemistry for Improved
Lipid Nanoparticle (LNP) Delivery of Messenger RNA (mRNA)</article-title>. <source>Biomater. Sci.</source>
<year>2022</year>, <volume>10</volume>, <fpage>549</fpage>&#x02013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1039/D1BM01454D</pub-id>.<pub-id pub-id-type="pmid">34904974</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="weblink" id="cit51"><collab>Avanti
Polar Lipids</collab>. <source>Phase Transition Temperatures
for Glycerophospholipids</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://avantilipids.com/tech-support/physical-properties/phase-transition-temps">https://avantilipids.com/tech-support/physical-properties/phase-transition-temps</uri>.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Su</surname><given-names>K.</given-names></name>; <name><surname>Shi</surname><given-names>L.</given-names></name>; <name><surname>Sheng</surname><given-names>T.</given-names></name>; <name><surname>Yan</surname><given-names>X.</given-names></name>; <name><surname>Lin</surname><given-names>L.</given-names></name>; <name><surname>Meng</surname><given-names>C.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; et al. <article-title>Reformulating
Lipid Nanoparticles for Organ-Targeted MRNA Accumulation and Translation</article-title>. <source>Nat. Commun.</source>
<year>2024</year>, <volume>15</volume> (<issue>1</issue>), <fpage>5659</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50093-7</pub-id>.<pub-id pub-id-type="pmid">38969646</pub-id>
</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Cheng</surname><given-names>Q.</given-names></name>; <name><surname>Lee</surname><given-names>S. M.</given-names></name>; <name><surname>Wei</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Farbiak</surname><given-names>L.</given-names></name>; <name><surname>Johnson</surname><given-names>L. T.</given-names></name>
<article-title>Hydrophobic
Optimization of Functional Poly(Tpae-Co-Suberoyl Chloride) for Extrahepatic
mRNA Delivery Following Intravenous Administration</article-title>. <source>Pharmaceutics</source>
<year>2021</year>, <volume>13</volume>, <fpage>1914</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13111914</pub-id>.<pub-id pub-id-type="pmid">34834329</pub-id>
</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Cheng</surname><given-names>Q.</given-names></name>; <name><surname>Wei</surname><given-names>T.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Johnson</surname><given-names>L. T.</given-names></name>; <name><surname>Farbiak</surname><given-names>L.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>Membrane-Destabilizing
Ionizable
Phospholipids for Organ-Selective MRNA Delivery and CRISPR&#x02013;Cas
Gene Editing</article-title>. <source>Nat. Mater.</source>
<year>2021</year>, <volume>20</volume>, <fpage>701</fpage>&#x02013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1038/s41563-020-00886-0</pub-id>.<pub-id pub-id-type="pmid">33542471</pub-id>
</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Lima</surname><given-names>T.</given-names></name>; <name><surname>Bernfur</surname><given-names>K.</given-names></name>; <name><surname>Vilanova</surname><given-names>M.</given-names></name>; <name><surname>Cedervall</surname><given-names>T.</given-names></name>
<article-title>Understanding
the Lipid and Protein Corona Formation on Different Sized Polymeric
Nanoparticles</article-title>. <source>Sci. Rep.</source>
<year>2020</year>, <volume>10</volume> (<issue>1</issue>), <fpage>1129</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-57943-6</pub-id>.<pub-id pub-id-type="pmid">31980686</pub-id>
</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Qiu</surname><given-names>M.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Muriph</surname><given-names>R.</given-names></name>; <name><surname>Ye</surname><given-names>Z.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Evans</surname><given-names>J.</given-names></name>; <name><surname>Henske</surname><given-names>E. P.</given-names></name>; <name><surname>Xu</surname><given-names>Q.</given-names></name>
<article-title>Lung-Selective
MRNA Delivery of Synthetic Lipid Nanoparticles for the Treatment of
Pulmonary Lymphangioleiomyomatosis</article-title>. <source>Proc. Natl.
Acad. Sci. U. S. A.</source>
<year>2022</year>, <volume>119</volume> (<issue>8</issue>), <elocation-id>e2116271119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2116271119</pub-id>.<pub-id pub-id-type="pmid">35173043</pub-id>
</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Carrasco</surname><given-names>M. J.</given-names></name>; <name><surname>Alishetty</surname><given-names>S.</given-names></name>; <name><surname>Alameh</surname><given-names>M. G.</given-names></name>; <name><surname>Said</surname><given-names>H.</given-names></name>; <name><surname>Wright</surname><given-names>L.</given-names></name>; <name><surname>Paige</surname><given-names>M.</given-names></name>; <name><surname>Soliman</surname><given-names>O.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>; <name><surname>Cleveland</surname><given-names>T. E.</given-names></name>; <name><surname>Grishaev</surname><given-names>A.</given-names></name>; et al. <article-title>Ionization and Structural Properties of mRNA
Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular
Administration</article-title>. <source>Commun. Biol.</source>
<year>2021</year>, <volume>4</volume> (<issue>1</issue>), <fpage>956</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02441-2</pub-id>.<pub-id pub-id-type="pmid">34381159</pub-id>
</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Loughrey</surname><given-names>D.</given-names></name>; <name><surname>Dahlman</surname><given-names>J. E.</given-names></name>
<article-title>Non-Liver mRNA Delivery</article-title>. <source>Acc.
Chem. Res.</source>
<year>2022</year>, <volume>55</volume>, <fpage>13</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.1c00601</pub-id>.<pub-id pub-id-type="pmid">34859663</pub-id>
</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Dilliard</surname><given-names>S. A.</given-names></name>; <name><surname>Siegwart</surname><given-names>D. J.</given-names></name>
<article-title>Passive, Active and Endogenous Organ-Targeted Lipid
and Polymer Nanoparticles for Delivery of Genetic Drugs</article-title>. <source>Nat. Rev. Mater.</source>
<year>2023</year>, <volume>8</volume>, <fpage>282</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1038/s41578-022-00529-7</pub-id>.<pub-id pub-id-type="pmid">36691401</pub-id>
</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Radmand</surname><given-names>A.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Beyersdorf</surname><given-names>J.</given-names></name>; <name><surname>Dobrowolski</surname><given-names>C. N.</given-names></name>; <name><surname>Zenhausern</surname><given-names>R.</given-names></name>; <name><surname>Paunovska</surname><given-names>K.</given-names></name>; <name><surname>Huayamares</surname><given-names>S. G.</given-names></name>; <name><surname>Hua</surname><given-names>X.</given-names></name>; <name><surname>Han</surname><given-names>K.</given-names></name>; <name><surname>Loughrey</surname><given-names>D.</given-names></name>; et al. <article-title>Cationic Cholesterol-Dependent LNP Delivery
to Lung Stem Cells, the Liver, and Heart</article-title>. <source>Proc.
Natl. Acad. Sci. U. S. A.</source>
<year>2024</year>, <volume>121</volume> (<issue>11</issue>), <elocation-id>e2307801120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2307801120</pub-id>.<pub-id pub-id-type="pmid">38437539</pub-id>
</mixed-citation></ref></ref-list></back></article>